US11186824B2 - Methods for engineering allogeneic T cell to increase their persistence and/or engraftment into patients - Google Patents

Methods for engineering allogeneic T cell to increase their persistence and/or engraftment into patients Download PDF

Info

Publication number
US11186824B2
US11186824B2 US15/556,558 US201615556558A US11186824B2 US 11186824 B2 US11186824 B2 US 11186824B2 US 201615556558 A US201615556558 A US 201615556558A US 11186824 B2 US11186824 B2 US 11186824B2
Authority
US
United States
Prior art keywords
cells
cell
seq
car
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US15/556,558
Other languages
English (en)
Other versions
US20180291343A1 (en
Inventor
Philippe Duchateau
Jean-Pierre Cabaniols
Julien Valton
Laurent Poirot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellectis SA
Original Assignee
Cellectis SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellectis SA filed Critical Cellectis SA
Assigned to CELLECTIS reassignment CELLECTIS ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DUCHATEAU, PHILIPPE, CABANIOLS, JEAN-PIERRE, POIROT, LAURENT, VALTON, JULIEN
Publication of US20180291343A1 publication Critical patent/US20180291343A1/en
Application granted granted Critical
Publication of US11186824B2 publication Critical patent/US11186824B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/33—Antibodies; T-cell engagers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/36—Immune checkpoint inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0006—Modification of the membrane of cells, e.g. cell decoration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/48—Regulators of apoptosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Definitions

  • the present invention relates to methods for developing engineered non-alloreactive T-cells for immunotherapy and more specifically to methods for increasing the persistence and/or the engraftment of allogeneic immune cells.
  • This method involves at least a step of inactivation of a gene implicated in the self/non-selfrecognition by the use of preferably specific rare-cutting endonuclease, followed by a step of contact of said engineered immune cells with at least one non-endogenous immunosuppressive polypeptide (such as PD-L1 ligand and/or CTLA-4 Ig).
  • This invention also relates to engineered immune cells and functional derivatives thereof, Chimeric Antigen Receptor (CAR), multichain CAR and their use thereof to enhance the efficiency of immunotherapy.
  • the invention opens the way to a safer strategy by reducing the risk of graft versus host disease GvHD and allows an affordable adoptive immunotherapy.
  • Adoptive immunotherapy which involves the transfer of autologous antigen-specific T cells generated ex vivo, is a promising strategy to treat viral infections and cancer.
  • the T cells used for adoptive immunotherapy can be generated either by expansion of antigen-specific T cells or redirection of T cells through genetic engineering (Park, Rosenberg et al. 2011). Transfer of viral antigen specific T cells is a well-established procedure used for the treatment of transplant associated viral infections and rare viral-related malignancies. Similarly, isolation and transfer of tumor specific T cells has been shown to be successful in treating melanoma.
  • CARs transgenic T cell receptors or chimeric antigen receptors
  • CARs are synthetic receptors consisting of a targeting moiety that is associated with one or more signaling domains in a single fusion molecule.
  • the binding moiety of a CAR consists of an antigen-binding domain of a single-chain antibody (scFv), comprising the light and variable fragments of a monoclonal antibody joined by a flexible linker. Binding moieties based on receptor or ligand domains have also been used successfully.
  • the signaling domains for first generation CARs are derived from the cytoplasmic region of the CD3zeta or the Fc receptor gamma chains.
  • First generation CARs have been shown to successfully redirect T cell cytotoxicity, however, they failed to provide prolonged expansion and anti-tumor activity in vivo.
  • Signaling domains from co-stimulatory molecules including CD28, OX-40 (CD134), and 4-1BB (CD137) have been added alone (second generation) or in combination (third generation) to enhance survival and increase proliferation of CAR modified T cells.
  • CARs have successfully allowed T cells to be redirected against antigens expressed at the surface of tumor cells from various malignancies including lymphomas and solid tumors (Jena, Dotti et al. 2010).
  • T lymphocytes are recovered from patients, genetically modified or selected ex vivo, cultivated in vitro in order to amplify the number of cells if necessary and finally infused into the patient.
  • the host may be manipulated in other ways that support the engraftment of the T cells or their participation in an immune response, for example pre-conditioning (with radiation or chemotherapy) and administration of lymphocyte growth factors (such as IL-2).
  • lymphocyte growth factors such as IL-2
  • Each patient receives an individually fabricated treatment, using the patient's own lymphocytes (i.e. an autologous therapy).
  • Autologous therapies face substantial technical and logistic hurdles to practical application, their generation requires expensive dedicated facilities and expert personnel, they must be generated in a short time following a patient's diagnosis, and in many cases, pretreatment of the patient has resulted in degraded immune function, such that the patient's lymphocytes may be poorly functional and present in very low numbers. Because of these hurdles, each patient's autologous cell preparation is effectively a new product, resulting in substantial variations in efficacy and safety. Ideally, one would like to use a standardized therapy in which allogeneic therapeutic cells could be pre-manufactured, characterized in detail, and available for immediate administration to patients. By allogeneic it is meant that the cells are obtained from individuals belonging to the same species but are genetically dissimilar.
  • allogeneic cells presently has many drawbacks.
  • HvG host versus graft rejection
  • allogeneic cells are able to engraft, but their endogenous TCR specificities recognize the host tissue as foreign, resulting in graft versus host disease (GvHD), which can lead to serious tissue damage and death.
  • GvHD graft versus host disease
  • glucocorticoid receptor This class of steroid hormones binds to the glucocorticoid receptor (GR) present in the cytosol of T cells resulting in the translocation into the nucleus and the binding of specific DNA motifs that regulate the expression of a number of genes involved in the immunologic process.
  • Treatment of T cells with glucocorticoid steroids results in reduced levels of cytokine production leading to T cell anergy and interfering in T cell activation.
  • Alemtuzumab also known as CAMPATH1-H, is a humanized monoclonal antibody targeting CD52, a 12 amino acid glycosylphosphatidyl-inositol-(GPI) linked glycoprotein (Waldmann and Hale 2005).
  • CD52 is expressed at high levels on T and B lymphocytes and lower levels on monocytes while being absent on granulocytes and bone marrow precursors.
  • Treatment with Alemtuzumab a humanized monoclonal antibody directed against CD52, has been shown to induce a rapid depletion of circulating lymphocytes and monocytes. It is frequently used in the treatment of T cell lymphomas and in certain cases as part of a conditioning regimen for transplantation.
  • the use of immunosuppressive drugs will also have a detrimental effect on the introduced therapeutic T cells. Therefore, to effectively use an adoptive immunotherapy approach in these conditions, the introduced cells would need to be resistant to the immunosuppressive treatment.
  • T cell receptors are cell surface receptors that participate in the activation of T cells in response to the presentation of antigen.
  • the TCR is generally made from two chains, alpha and beta, which assemble to form a heterodimer and associates with the CD3-transducing subunits to form the T-cell receptor complex present on the cell surface.
  • Each alpha and beta chain of the TCR consists of an immunoglobulin-like N-terminal variable (V) and constant (C) region, a hydrophobic transmembrane domain, and a short cytoplasmic region.
  • variable region of the alpha and beta chains are generated by V(D)J recombination, creating a large diversity of antigen specificities within the population of T cells.
  • T cells are activated by processed peptide fragments in association with an MHC molecule, introducing an extra dimension to antigen recognition by T cells, known as MHC restriction.
  • MHC restriction Recognition of MHC disparities between the donor and recipient through the T cell receptor leads to T cell proliferation and the potential development of GVHD. It has been shown that normal surface expression of the TCR depends on the coordinated synthesis and assembly of all seven components of the complex (Ashwell and Klusner 1990).
  • TCRalpha or TCRbeta can result in the elimination of the TCR from the surface of T cells preventing recognition of alloantigen and thus GVHD.
  • TCR disruption results in the elimination of the CD3 signaling component and alters the means of further T cell expansion.
  • Adaptive immune response is a complex biological system where numerous cellular components interact.
  • Professional Antigen Presenting Cells APC
  • helper T cells in the context of MHC Class II molecules.
  • Activated helper T cells will in turn stimulate B cells response and cytotoxic T (CTL) cells response.
  • CTL cytotoxic T
  • CTL recognize foreign peptides presented by MHC Class I molecules but in the case of alloreactivity, recognize and kill cells bearing foreign MHC Class I.
  • MHC Class I molecules are composed of 2 entities: the highly polymorphic, transmembrane heavy chain and a small invariant polypeptide, the ⁇ 2-microglobuline ( ⁇ 2-m) encoded by B2M gene.
  • MHC Class I heavy chain at the cell surface requires its association with the ⁇ 2-m. Hence, abrogation of ⁇ 2-m expression in CAR T cells will impair MHC Class I expression and make them invisible to host CTL.
  • MHC Class I deficient CAR T cells are susceptibe to lysis by host NK cells, which target cells lacking MHC Class I molecules [Ljunggren H G et al. (1990), Immunl Today. 11:237-244].
  • NK cells exert cytotoxic functions towards the cells they interact with based on the balance between activating and inhibitory signals they received through different monomorphic or polymorphic receptors.
  • One central activating receptor on human NK cells is NKG2D and its ligands include proteins such as MICA, MICB, ULBP1, ULBP2, ULBP3 [Raulet D H, (2003), Nature Reviews Immunology 3 (10): 781-79].
  • the inhibitory signal is mediated through the interaction between NK receptors like LIR-1/ILT2 and MHC Class I molecules [Ljunggren H G et al. (1990), Immunl Today. 11:237-244].
  • HCMV genome encodes proteins that are able to prevent MHC Class I surface expression (i.e. US2, US3, US6 and US11) while expressing a MHC class I homolog protein (UL18) that acts as a decoy to block NK-mediated cell lysis [Kim, Y et al. (2008), PLOS Pathogens. 4: e1000123, and Wilkinson G. et al. (2010). J Clin Virol. 41(3):206-212].
  • HCMV interferes with the NKG2D pathway by secreting a protein able to bind NKG2D ligands and prevent their surface expression [Welte S A et al. (2003), Eur J Immunol 33 (1): 194-203].
  • NKG2D ligands such as ULBP2, MICB or MICA (Waldhauer I, Steinle A (2003). Proteolytic release of soluble UL16-binding protein 2 from tumor cells. Cancer Res 2006; 66(5): 2520-2526; Salih H R et al. (2006), Hum Immunol. 2006 March; 67(3):188-95; Salih H R et al. (2003) Blood. 2003 Aug. 15; 102(4):1389-96; Salih H R et al. (2002) J Immunol.; 169(8):4098-102].
  • ISU ImmunoSuppressive Unit
  • FP protein Kinase C
  • Both ISU and FP have been shown to be inmmunosuppressive as whole protein transmembrane protein, truncated transmembrane protein or synthetic peptides.
  • T-cell mediated immunity includes multiple sequential steps regulated by a balance between co-stimulatory and inhibitory signals that fine-tune the immunity response.
  • the inhibitory signals referred to as immune checkpoints are crucial for the maintenance of self-tolerance and also to limit immune-mediated collateral tissue damage.
  • the expression of immune checkpoints protein can be deregulated by tumours. The ability of tumours to co-opt these inhibitory pathways represents an important mechanism in immune resistance and limits the success of immunotherapy.
  • One of promising approaches to activating therapeutic T-cell immune response is the blockade of these immune checkpoints (Pardoll 2012).
  • Immune checkpoints represent significant barriers to activation of functional cellular immunity in cancer, and antagonistic antibodies specific for inhibitory ligands on T cells including CTLA4 and programmed death-1 (PD-1) are examples of targeted agents being evaluated in the clinics.
  • Cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4; also known as CD152) downregulates the amplitude of T cell activation and treatment with antagonist CTLA4 antibodies (ipilimumab) has shown a survival benefit in patients with melanoma (Robert and Mateus 2011).
  • Programmed cell death protein 1 (PD1 or PDCD1 also known as CD279) represent another very promising target for immunotherapy (Pardoll and Drake 2012; Pardoll 2012).
  • PD1 limits T cell effector functions in peripheral tissue at the time of an inflammatory response to infection and to limit autoimmunity.
  • the first clinical trial with PD1 antibody shows some cases of tumour regression (Brahmer, Drake et al. 2010).
  • Multiple additional immune checkpoint protein represent promising targets for therapeutic blockade based on recently studies.
  • WO2013/173223A application describes a method for immunotherapy wherein the PD-1-PD-L1 pathway is disrupted by the administration of antibodies against PD-1 and/or PD-L1.
  • This inhibitory immunoregulator is used as biomarker to enable patient selection and guide on-treatment management.
  • tumor-targeted T cells modified to secrete the interferon IL-12 can eradicate systemic tumors in murine model, without the need of prior conditioning such as irradiation, lymphodepleting chemotherapy and/or additional cytokine support.
  • This method consists in creating a local immune protection by engineering therapeutic cells to ectopically express and/or secrete immunosuppressive polypeptides at or through the cell membrane. They found that a various panel of such polypeptides in particular antagonists of immune checkpoints, or derived from viral envelope or NKG2D ligand could enhance persistence and/or an engraftment of allogeneic immune cells into the host. For a better efficacy, this local immunosuppressive effect is completed by the inactivation of gene involved in the self/non-self recognition, making these engineered immune cell for engraftment, available as an “off the shelf” product.
  • the present invention discloses methods to engineer immune cell, such as T cells, to make them suitable for immunotherapy purposes by increasing their persistence and/or easing their engraftment in host organism, reducing thereby the risk of graft versus host disease (GvHD). More particularly, the invention relates to a method, wherein at least one endogenous gene encoding a polypeptide involved in the self and non-self antigen recognition is inactivated in one immune cells, followed by contacting said engineered immune cells with at least one non-endogenous immunosuppressive polypeptide.
  • the inactivation is performed on TCR and/or beta2M gene, preferably by using a specific rare-cutting endonuclease, such as a TALE-nuclease.
  • the contacting step is realized by the expression of inactive PD1 and/or CTLA-4 ligand by the immune cell itself.
  • HvG host-versus-graft
  • Other alternatives according to the invention provide with the expression of viral MHC homolog, NKG2D ligand, and/or viral env immune suppressive domain (ISU) or the viral FP protein.
  • the incubation of engineered immune cells with at least one non-endogenous immunosuppressive polypeptide may be used instead of the expression of immunosuppressive polypeptides.
  • CD80/CD86 antibodies are preferred as immune suppressive polypeptide to be used in said incubation.
  • the modified immune cells relevant for immunotherapy may further comprise exogenous recombinant polynucleotides encoding Chimeric Antigen Receptors (CAR) for specific cell recognition.
  • CAR Chimeric Antigen Receptors
  • the resulting isolated cells or cell lines comprising any of the proteins, polypeptides or vectors described in this specification are dedicated for use as therapeutic products, ideally as “off the shelf” products with reduced graft-versus-host disease (GvHD) risk and extended life span.
  • GvHD graft-versus-host disease
  • FIG. 1 Schematic representation of the potential interactions between an allogeneic CAR T cell with diverse host immune cells (CD8+ and CD4+ T cell, APC such as dendritic cell and NK cell), the CAR T cell having no additional genetic modification.
  • Sign (+) represents activation and sign ( ⁇ ) inhibition.
  • CAR T cell is activated by encountering targeted tumor cell which displays an antigen cell surface recognized by the scFvs of the CAR.
  • Interaction between allogeneic CAR T cell and host NK cell is inhibited by the recognition of the MHC I by the inhibitor of the NK cell.
  • Activation of the host cytotoxic T cell (CD8+ T cell) takes place by the binding by TCR of the MHC I components of the CAR T cell.
  • the action of host NK cell on allogeneic T CAR cell is inhibited via the MHCI recognition.
  • FIG. 2 Schematic representation of the potential interactions between an allogeneic CAR T cell with diverse host immune cells (CD8+ and CD4+ T cell, APC such as dendritic cell and NK cell); the CAR T cell expressing secreted CTLA-4 Igs.
  • Sign (+) represents activation and sign ( ⁇ ) inhibition.
  • CAR T cell is activated by encountering targeted tumor cell which displays an antigen cell surface recognized by the scFvs of the CAR.
  • the interaction between NK cell and CAR T cell remains unchanged.
  • the secreted CLTA-4 Igs bind to the CD80/CD86 antigen on the surface of APC cell and tumor cell, therefore inactivating the interaction between APC cell (such a dendritic cell here) and the CAR T cell.
  • APC such as dendritic cell and NK cell
  • FIG. 3 Schematic representation of the potential interactions between an allogeneic CAR T cell with diverse host immune cells (CD8+ and CD4+ T cell, APC such as dendritic cell and NK cell); the CAR T cell expressing membrane-bound PD-L1 and whose PD-1 gene is inactivated by KO. Sign (+) represents activation and sign ( ⁇ ) inhibition. The potential interaction between CAR T cell with the tumor cell and the NK cell remain unchanged. The expression of PD-L1 by the allogeneic CAR T cell makes it insensitive to the host CD8+ T cell due to the binding PD-L1 to the PD-1 receptor of the latter. Thus, the PD-L1 triggers T cells inhibitory pathway in the patient's T cells, and this effect is more pronounced when the PD-1 gene of the allogeneic is inactivated.
  • CD8+ and CD4+ T cell, APC such as dendritic cell and NK cell
  • Sign (+) represents activation and sign ( ⁇ ) inhibition.
  • FIG. 4 Schematic representation of the potential interactions between an allogeneic CAR T cell with diverse host immune cells (CD8+ and CD4+ T cell, APC such as dendritic cell and NK cell); the CAR T cell expressing secreted PD-L1 and whose PD-1 gene is inactivated by KO. Sign (+) represents activation and sign ( ⁇ ) inhibition. The potential interaction between CAR T cell with the tumor cell and with the NK cell remain unchanged. The secreted PD-L1 by the allogeneic CAR T cell can bind to host CD8+ and CD4+ T cell by their PD-1 receptors, inhibiting the PD-L1/PD-1 pathway. Thus, the PD-L1 triggers T cells inhibitory pathway in the patient's T cells, and this effect is more pronounced when the PD-1 gene of the allogeneic is inactivated.
  • CD8+ and CD4+ T cell, APC such as dendritic cell and NK cell
  • Sign (+) represents activation and sign ( ⁇ ) inhibition.
  • FIG. 5 Schematic representation of the potential interactions between an allogeneic CAR T cell with diverse host immune cells (CD8+ and CD4+ T cell, APC such as dendritic cell and NK cell), the CAR T cell expressing a viral env immunosuppressive domain (ISU).
  • Sign (+) represents activation and sign ( ⁇ ) inhibition.
  • the potential interaction between CAR T cell with the tumor cell and with the NK cell remain unchanged.
  • the expression of viral ISU appears to inhibit the recognition of the allogeneic CAR T cell by the host T cells and APCs cells maybe by the reduced production of IL-10 interleukin, and thus creating an immunosuppressive effect.
  • FIG. 6 Schematic representation of the potential interactions between an allogeneic CAR T cell with diverse host immune cells (CD8+ and CD4+ T cell, APC such as dendritic cell and NK cell), the CAR T cell having its B2M gene inactivated by KO. Sign (+) represents activation and sign ( ⁇ ) inhibition. The potential interaction between CAR T cell with the tumor cell remains unchanged. The inactivation of B2M gene which is one component of the MCHI, renders the latter non-functional in regards to the interactions with host cytotoxic T cell (CD8+) and with NK cell. Then, NK cell can exert its activation on allogeneic CART cell via activator pathway such NKG2D/NKG2D ligand.
  • CD8+ and CD4+ T cell, APC such as dendritic cell and NK cell
  • FIG. 7 Schematic representation of the potential interactions between an allogeneic CAR T cell with diverse host immune cells (CD8+ and CD4+ T cell, APC such as dendritic cell and NK cell), the CAR T cell having its B2M gene inactivated by KO and expressing viral MHCI homolog.
  • Sign (+) represents activation and sign ( ⁇ ) inhibition.
  • the potential interaction between CAR T cell with the tumor cell remains unchanged.
  • the expression of viral MHCI homolog renders the interaction with NK cell inoperative via MHCI/inhibitor receptor.
  • the double genetic modification of allogeneic CAR T cells by KO of B2M combined with the expression of viral MHCI homolog strengthens their immunosuppressive protection.
  • FIG. 8 Schematic representation of the potential interactions between an allogeneic CAR T cell with diverse host immune cells (CD8+ and CD4+ T cell, APC such as dendritic cell and NK cell), the CAR T cell having its B2M gene inactivated by KO and expressing a soluble NKG2D ligand. Sign (+) represents activation and sign ( ⁇ ) inhibition. The potential interaction between CAR T cell with the tumor cell remains unchanged. As for the preceding figure (only B2M KO), the interaction between CAR T cell and host CD8+ T cell is alleviated. The expression of soluble NKG2D ligand is another way to inactivate the interaction with NK cell.
  • CD8+ and CD4+ T cell, APC such as dendritic cell and NK cell
  • the soluble NKG2D ligand can bind to NKG2D receptor on NK cell but exerts no action, in contrast to the NKG2D ligand of CAR T cell with which it exerts an inhibitory competition.
  • the double genetic modification of allogeneic CAR T cells by KO of B2M combined with the expression of soluble NKG2D ligand strengthens their immunosuppressive protection.
  • FIG. 9 General scheme of allogeneic CAR T cell adoptive immunotherapy illustrating the potential host versus graft reaction (HvG).
  • HvG human immunotherapy
  • CAR anti-CD19 chimeric antigen receptor
  • ALL acute lymphoblastic leukemia
  • FIG. 10 Scheme describing the re-expression of PD-L1 to prevent the HvG reaction taking place in the host patient after allogeneic CAR T cells adoptive transfer.
  • A. Scheme of HvG reaction prevention via re-expression of PD-L1 at the cell surface of primary T cells.
  • FIG. 11 Scheme describing the HvG reaction including the host antigen presenting cells (APC) and host T cells along with the names of the receptors involved in their activation in the presence of Allogeneic T cells.
  • A Scheme of HvG reaction.
  • B Scheme of HvG prevention in excretion of CTLA4-Ig by allogeneic T cells.
  • FIG. 12 A, B & C Characterization of the expression of PD-L1 at the surface of T cells or CAR tool T cells by flow cytometry.
  • FIG. 13 Specific cell lysis activity of engineered CAR T cell expressing PD-L1 toward relevant and non-relevant tumor cells (Daudi and K562 cells respectively). A and B indicate different blood donors.
  • FIG. 14 ELISA detection of CTLA4a Ig and CTLA4b Ig excretion by CAR T cells in the culture media.
  • FIG. 15 Specific Cell lysis activity of Engineered CAR T cell expressing CTLA4a Ig toward relevant and non-relevant tumor cells (Daudi and K562 cells respectively).
  • FIG. 16 FACS analysis of ⁇ 2-m expression in T cells. Untransfected (top) and transfected T cells (middle and bottom) are analysed by FACS for viability (left) and ⁇ 2-m expression (right).
  • FIG. 17 Detection of CTLA4Ig in the culture media supernatant of engineered CAR T cells transduced with a control LV (PD-L1), CTLA4Ig LV alone or co transduced with PD-L1 and CTLA4Ig LV at a MOI of 5.
  • PD-L1 control LV
  • supernatants from 14 day old culture are tested by ELISA at 1/1000e dilution (hatched bar) or 1/5000e dilution (dark bar).
  • the grey bar represents the mean titer from both dilution.
  • FIG. 18 Mixed Lymphocytes reaction for quantification of CFSE negative T cells from donor 1 (grey bars), quantification of CD3+ T cells (black bars) and T cells viability (hatched bars) in response to the indicated stimulations.
  • D1 and D2 correspond to donor 1 and donor 2 respectively.
  • PBMCs from donor 1 without any treatment have been cultured alone;
  • PBMCs from donor 1, which have been submitted to a treatment with increasing concentration of PHA (PhytoHemAgglutinin—10 ⁇ g/ml, a T cell mitogen) are cultured alone;
  • PHA Physical HemAgglutinin—10 ⁇ g/ml, a T cell mitogen
  • PBMCs from donor 1 are co-cultured with untransduced T cells from donor 2;
  • PBMCs from donor 1 are co-cultured with PD-L1 transduced T cells from donor 2;
  • PBMCs from donor 1 are co-cultured with CTLA4Ig transduced T cells from donor 2;
  • PBMCs from donor 1 are co-cultured with PD-L1 and CTLA4Ig co-transduced T cells from donor 2.
  • FIG. 19 Cytotoxicity assay in which indicated differently engineered CAR T cells (as shown under the graph) are incubated at a E:T ratio of 10:1 with specific target cells (MOLM-13; expressing CD123 antigen) and control negative cells (Daudi) for 4 hours. Target cell death is measured by flow cytometry and is normalized for non-specific killing (Daudi).
  • MOLM-13 specific target cells
  • Daudi control negative cells
  • FIG. 20 Cytotoxicity assay in which Indicated differently engineered CAR T cells (as shown under the graph) are incubated at E:T ratio of 10:1 (hatched bar), 5:1 (dark bars) and 1:1 (grey bars) with specific target cells (MOLM-13) and control negative cells (Daudi) for 4 hours. Target cell death is measured by flow cytometry and is normalized for non-specific killing (Daudi).
  • FIG. 21 Outline scheme for in vivo experiment. NOG mice are first injected with MOLM-13 (luc/GFP) tumor cell line 7 days before engineered CAR T cells injection. Tumor progression is monitored via bioluminescence (Biolum.) analysis and overall survival.
  • MOLM-13 luc/GFP
  • FIG. 22 Engineered T cells are monitored for the CAR CD123 and PD-L1 cell surface expression by flow cytometry.
  • FIG. 23 Bioluminescence imaging from D-1 to D14 showing the tumors in the NOG mice. The dark spots in the photos represent the tumors.
  • the different groups of T cells injected into the mice are presented as follows.
  • FIG. 23A untransfected T cells (no CAR T cells) or T cells transfected by anti-CD123 CAR (CAR T CD123).
  • FIG. 23A untransfected T cells (no CAR T cells) or T cells transfected by anti-CD123 CAR (CAR T CD123).
  • T cells transfected by anti-CD123 CAR and transduced with CTLA4Ig (CAR T CD123/CTLA4Ig); T cells transfected by anti-CD123 CAR and transduced with PD-L1 (CAR T CD123/PDL1); T cells transfected by anti-CD123 CAR and transduced with CTLA4Ig and with PD-L1 (CAR T CD123/PDL1/CTLA4Ig).
  • FIG. 24 Schematic representation of the different single chain chimeric antigen receptor CAR Architecture (V1 to V6) with the components: VH and VL chains specific to antigen, hinge, transmembrane domain (TM), co-stimulatory domain (4-1BB) and signaling transduction domain (CD3zeta), optionally with linker(s).
  • V1 to V6 Schematic representation of the different single chain chimeric antigen receptor CAR Architecture (V1 to V6) with the components: VH and VL chains specific to antigen, hinge, transmembrane domain (TM), co-stimulatory domain (4-1BB) and signaling transduction domain (CD3zeta), optionally with linker(s).
  • Table 3 Polynucleotide sequences of plasmidic constructs expressing CLTA-4a, CTLA-4b and PD-L1.
  • Table 4 Polypeptide sequences of ISU domain variants from diverse virus.
  • Table 5 Polypeptide sequences of a viral MHC homolog (UL18) and a panel of NKG2D ligands.
  • Table 6 Aminoacid sequences of FP polypeptide from natural and artificial origins.
  • Table 7 Description of the TRAC and TRBC TALE-nucleases and sequences of the TALE-nucleases target sites in the human corresponding genes.
  • the present invention relates to methods for new adoptive immunotherapy strategies in treating cancer and infections.
  • Method to increase the persistence and/or the engraftment of allogeneic immune cells comprising:
  • step c) The method of any one of embodiment 1 to 4, wherein said expression or contact in step c) does specifically inhibit CD8+ T cells.
  • step c) is performed by the expression in said immune cells at least one non-endogenous polynucleotide directing the secretion of at least one non-endogenous immunosuppressive polypeptide.
  • step c) contains additionally an inactivation of the expression of a gene encoding PD-1.
  • step b) The method according to any one of embodiment 1 to 8, wherein said polypeptide in step b) is chosen amongst TCR, MHC class of class I component, b-2 microglobulin (B2M), TAP1 and large multifunctional protease 2.
  • step c) The method according to any one of embodiment 1 to 9, wherein said polypeptide in step c) is chosen amongst PDL-1, CTLA-4, viral MHC homolog, NKG2D ligand, viral env immune suppressive domain (ISU) or the viral FP protein.
  • said polypeptide in step c) is chosen amongst PDL-1, CTLA-4, viral MHC homolog, NKG2D ligand, viral env immune suppressive domain (ISU) or the viral FP protein.
  • step b) is performed by the inactivation of the B2M and step c) is performed by the expression of inactive PDL-1 ligand in said allogeneic immune cells.
  • step c) The method according to any one of embodiment 1 to 11, wherein the additional modification in step c) is performed by the expression of CTLA-4 immunoglobulins in said allogeneic immune cells.
  • step b) is performed by the inactivation of the TCR and step c) is performed by the expression of inactive PDL-1 ligand by said allogeneic immune cells.
  • step c) is performed by expressing viral env immune suppressive domain (ISU) chosen from FeLV, MLV, HERV or the viral FP protein.
  • ISU immune suppressive domain
  • step b) is performed by the inactivation of the B2M and step c) is performed by the expression of viral env immune suppressive domain (ISU) by said allogeneic immune cells.
  • ISU immune suppressive domain
  • step b) is performed by the inactivation of the TCR and step c) is performed by the expression of viral env immune suppressive domain (ISU) by said allogeneic immune cells.
  • ISU immune suppressive domain
  • nucleic acid molecule encoding viral env immune suppressive domain (ISU) to be expressed shares at least 80%, preferably 90% and more preferably 95% of identity with SEQ ID NO: 19-38.
  • step b) is performed by the inactivation of the B2M and step c) is performed by the expression of viral FP protein by said allogeneic immune cells.
  • step b) is performed by the inactivation of the TCR and step c) is performed by the expression of viral FP protein by said allogeneic immune cells.
  • nucleic acid molecule encoding viral FP protein to be expressed shares at least 80%, preferably 90% and more preferably 95% of identity with SEQ ID NO: 48-50.
  • step b) is performed by the inactivation of the B2M and step c) is performed by the expression of NKG2G ligand by said allogeneic immune cells.
  • step b) is performed by the inactivation of the TCR and step c) is performed by the expression of NKG2G ligand by said allogeneic immune cells.
  • step b) is performed by the inactivation of the B2M and step c) is performed by the expression of viral MHC homolog UL18 protein by said allogeneic immune cells.
  • step b) is performed by the inactivation of the TCR and step c) is performed by the expression of viral MHC homolog UL18 protein by said allogeneic immune cells.
  • nucleic acid molecule encoding viral MHC homolog UL18 to be expressed shares at least 80%, preferably 90% and more preferably 95% of identity with SEQ ID NO: 39.
  • step c) is performed by the incubation of said immune in at least one non-endogenous immunosuppressive polypeptide.
  • step b) The method according to anyone of embodiment 1 or 30, wherein gene inactivation in step b) is performed by using a TAL-nuclease, meganuclease, zing-finger nuclease (ZFN), or RNA guided endonuclease.
  • TAL-nuclease TAL-nuclease
  • meganuclease TAL-nuclease
  • ZFN zing-finger nuclease
  • RNA guided endonuclease RNA guided endonuclease
  • step b) The method according to anyone of embodiment 1 or 31, wherein gene inactivation in step b) is performed using a TAL-nuclease.
  • step b) The method according to any one of embodiment 1 to 31, wherein gene inactivation in step b) is performed by using a RNA-guided endonucleases.
  • step b) The method according to any one of embodiment 1-10, 11-15, 17-18, 20-21, 23-25 or 27-34 wherein gene inactivation in step b) is performed by using a nucleic acid molecule that inhibits the expression of a gene encoding TCR.
  • step b) The method according to any one of embodiments 1-12, 13-16, 18-19, 21-22, 24-26 or 28-34 wherein inactivation gene in step b) is performed by using a nucleic acid molecule that inhibits the expression of a gene encoding B2M.
  • CAR Chimeric Antigen Receptor
  • said Chimeric Antigen Receptor comprises scFv (VH and VL chains) having as antigenic target sequence of over 80% identity, preferably over 90%, and more preferably over 95% with SEQ ID NO 67 (CD19 antigen), SEQ ID NO 68 (CD38 antigen), SEQ ID NO 69 (CD123 antigen), SEQ ID NO 70 (CS1 antigen), SEQ ID NO 71 (BCMA antigen), SEQ ID NO 72 (FLT-3 antigen), SEQ ID NO 73 (CD33 antigen), SEQ ID NO 74 (CD70 antigen), SEQ ID NO 75 (EGFR-3v antigen) and SEQ ID NO 76 (WT1 antigen).
  • SEQ ID NO 67 CD19 antigen
  • SEQ ID NO 68 CD38 antigen
  • SEQ ID NO 69 CD123 antigen
  • SEQ ID NO 70 CS1 antigen
  • SEQ ID NO 71 BCMA antigen
  • SEQ ID NO 72 FLT-3 antigen
  • SEQ ID NO 73 CD33 antigen
  • composition comprising at least one engineered T-cell according to any one of embodiments 42 to 47.
  • Method to increase the persistence and/or the engraftment of allogeneic immune cells in presence of host immune cells comprising:
  • step b) is chosen amongst TCR, MHC class of class I component, b-2 microglobulin (B2M), TAP1 and large multifunctional protease 2.
  • step c) is performed by the expression in said immune cells at least one non-endogenous polynucleotide encoding for one non-endogenous immunosuppressive polypeptide bound to the membrane surface of said immune cells.
  • nucleic acid molecule encoding PD-L1 ligand under a membrane-bound form to be expressed shares at least 80%, preferably 90% and more preferably 95% of identity with SEQ ID NO:18.
  • step c) is performed by the expression in said immune cells at least one non-endogenous polynucleotide encoding for one non-endogenous immunosuppressive polypeptide under a secreted form in said immune cells.
  • step c) is performed by the expression in said immune cells at least one non-endogenous polynucleotide encoding for one non-endogenous immunosuppressive polypeptide under a secreted form in said immune cells.
  • the nucleic acid molecule encoding CTLA-4 immunoglobulins to be expressed shares at least 80%, preferably 90% and more preferably 95% of identity with SEQ ID NO: 16-17.
  • step c) is performed by contacting said host immune cells with both non-endogenous immunosuppressive polypeptide PD-L1 ligand and CTLA-4 immunoglobulins.
  • step c) is performed by the step c) is performed by the expression in said immune cells of both non-endogenous immunosuppressive polypeptide PD-L1 ligand and CTLA-4 immunoglobulins.
  • step c) The method according to any one of embodiment 1 to 3, wherein said expression or contact in step c) does not specifically inhibit T regulatory cells.
  • step c) The method according to any one of embodiment 1 to 15, wherein said expression or contact in step c) does specifically inhibit host CD8+ T cells.
  • step c) contains additionally an inactivation of the expression of a PD-1 gene.
  • step c) is performed by the expression in said immune cells at least one non-endogenous polynucleotide encoding for PD-L1 ligand under a membrane-bound form, and a further modification of said allogeneic cells is performed by an inactivation of the expression of PD-1 gene.
  • step c) is performed by the expression in said immune cells at least one non-endogenous polynucleotide directing the secretion of CTLA4 Ig, and a further modification of said allogeneic cells is performed by an inactivation of the expression of PD-1 gene.
  • step c) is performed by the step c) is performed by the expression in said immune cells of both non-endogenous immunosuppressive polypeptide PD-L1 ligand and CTLA-4 immunoglobulins, and a further modification of said allogeneic immune cells is performed by an inactivation of the expression of PD-1 gene.
  • step c) The method according to any one of embodiment 1 to 16, wherein said polypeptide in step c) is chosen amongst PD-L1, CTLA-4, viral MHC homolog, NKG2D ligand, viral env immune suppressive domain (ISU) or the viral FP protein.
  • said polypeptide in step c) is chosen amongst PD-L1, CTLA-4, viral MHC homolog, NKG2D ligand, viral env immune suppressive domain (ISU) or the viral FP protein.
  • step b) is performed by the inactivation of the B2M and step c) is performed by the expression of PD-L1 ligand in said allogeneic immune cells.
  • step b) is performed by the inactivation of the TCR and step c) is performed by the expression of PD-L1 ligand by said allogeneic immune cells.
  • step c) is performed by expressing viral env immune suppressive domain (ISU) chosen from FeLV, MLV, HERV or the viral FP protein.
  • ISU immune suppressive domain
  • step b) is performed by the inactivation of the B2M and step c) is performed by the expression of viral env immune suppressive domain (ISU) by said allogeneic immune cells.
  • ISU immune suppressive domain
  • step b) is performed by the inactivation of the TCR and step c) is performed by the expression of viral env immune suppressive domain (ISU) by said allogeneic immune cells.
  • ISU immune suppressive domain
  • nucleic acid molecule encoding viral env immune suppressive domain (ISU) to be expressed shares at least 80%, preferably 90% and more preferably 95% of identity with SEQ ID NO: 19-38.
  • step b) is performed by the inactivation of the B2M and step c) is performed by the expression of viral FP protein by said allogeneic immune cells.
  • step b) is performed by the inactivation of the TCR and step c) is performed by the expression of viral FP protein by said allogeneic immune cells.
  • nucleic acid molecule encoding viral FP protein to be expressed shares at least 80%, preferably 90% and more preferably 95% of identity with SEQ ID NO: 48-50.
  • step b) is performed by the inactivation of the B2M and step c) is performed by the expression of NKG2G ligand by said allogeneic immune cells.
  • step b) is performed by the inactivation of the TCR and step c) is performed by the expression of NKG2G ligand by said allogeneic immune cells.
  • nucleic acid molecule encoding NKG2G ligand to be expressed shares at least 80%, preferably 90% and more preferably 95% of identity with SEQ ID NO: 40-47.
  • step b) is performed by the inactivation of the B2M and step c) is performed by the expression of viral MHC homolog UL18 protein by said allogeneic immune cells.
  • step b) is performed by the inactivation of the TCR and step c) is performed by the expression of viral MHC homolog UL18 protein by said allogeneic immune cells.
  • nucleic acid molecule encoding viral MHC homolog UL18 to be expressed shares at least 80%, preferably 90% and more preferably 95% of identity with SEQ ID NO: 39.
  • step c) is performed by the incubation of said immune in at least one non-endogenous immunosuppressive polypeptide.
  • step b) The method according to anyone of embodiment 1 to 40, wherein gene inactivation in step b) is performed by using a TAL-nuclease, meganuclease, zing-finger nuclease (ZFN), or RNA guided endonuclease.
  • TAL-nuclease TAL-nuclease
  • meganuclease TAL-nuclease
  • ZFN zing-finger nuclease
  • RNA guided endonuclease RNA guided endonuclease
  • step b) The method according to embodiment 41, wherein gene inactivation in step b) is performed using a TAL-nuclease.
  • step b) The method according to embodiment 41, wherein gene inactivation in step b) is performed by using a RNA-guided endonucleases.
  • step b) The method according to any one of embodiments 1-18, 20-22, 24-25, 27-28, 30-32 or 34-41 wherein gene inactivation in step b) is performed by using a nucleic acid molecule that inhibits the expression of a gene encoding TCR.
  • step b) The method according to any one of embodiments 1-17, 20-2, 25-26, 28-29, 31-33 or 35-41 wherein inactivation gene in step b) is performed by using a nucleic acid molecule that inhibits the expression of a gene encoding B2M.
  • CAR Chimeric Antigen Receptor
  • said Chimeric Antigen Receptor comprises scFv (VH and VL chains) having as antigenic target sequence of over 80% identity, preferably over 90%, and more preferably over 95% with SEQ ID NO 67 (CD19 antigen), SEQ ID NO 68 (CD38 antigen), SEQ ID NO 69 (CD123 antigen), SEQ ID NO 70 (CS1 antigen), SEQ ID NO 71 (BCMA antigen), SEQ ID NO 72 (FLT-3 antigen), SEQ ID NO 73 (CD33 antigen), SEQ ID NO 74 (CD70 antigen), SEQ ID NO 75 (EGFR-3v antigen) and SEQ ID NO 76 (WT1 antigen)
  • step c) is performed by the step c) is performed by the expression in said allogeneic immune cells of non-endogenous immunosuppressive polypeptide PD-L1 ligand and/or CTLA-4 immunoglobulins, said allogeneic immune cells being further modified by the expression of an anti-CD123 Chimeric Antigen Receptor.
  • composition comprising at least one engineered T-cell according to any one of embodiments 54 to 59.
  • the inventors have shown that some genes, when they are expressed in allogeneic immune cells, could allow an increase of their persistence in the host organism for a better efficacy.
  • the present invention relates to a method to increase the persistence and/or the engraftment of allogeneic immune cells, preferably in presence of host immune cells, comprising:
  • Said non-endogenous immunosuppressive polypeptide is expected to have the effect of preventing host immune cells from interacting with allogeneic immune cells.
  • Persistence refers to the ability of cells to resist rejection and remain and/or increase in number over time (e.g., days, weeks, months, years) in vivo.
  • the engineered immune cells of the present invention can be found in patient's blood at least 10 days, preferably at least 20 days, more preferably at least 25 days and even more preferably at least 30 days after infusion into said patient.
  • Endgraftment refers to the process of cellular contact and incorporation into an existing site of interest in vivo.
  • “increased persistence and/or engraftment” is meant that the number of allogeneic immune cells, engineered to render them persistent, remains higher during the course of the treatment, compared to the case where non-engineered ones (i.e non persistent) are administered to the patient.
  • Such improved persistence and/or engraftment in allogeneic immune cells (e.g. T cells) to be injected to a patient are part of the immunological tolerance (or “tolerisation”) which describes a state of unresponsiveness of the host immune system with respect to said immune cells, whereas said immune cells retain the capacity to elicit an immune response.
  • MHC Major Histocompatibility Complex
  • the genetic modification of the method relies on the expression, in provided cells to engineer, of one rare-cutting endonuclease such that said rare-cutting endonuclease specifically catalyzes cleavage in one targeted gene thereby inactivating said targeted gene.
  • the nucleic acid strand breaks caused by the rare-cutting endonuclease are commonly repaired through the distinct mechanisms of homologous recombination or non-homologous end joining (NHEJ).
  • NHEJ non-homologous end joining
  • NHEJ non-homologous end joining
  • the genetic modification step of the method further comprises a step of introduction into cells an exogeneous nucleic acid comprising at least a sequence homologous to a portion of the target nucleic acid sequence, such that homologous recombination occurs between the target nucleic acid sequence and the exogeneous nucleic acid.
  • said exogenous nucleic acid comprises first and second portions which are homologous to region 5′ and 3′ of the target nucleic acid sequence, respectively.
  • Said exogenous nucleic acid in these embodiments also comprises a third portion positioned between the first and the second portion which comprises no homology with the regions 5′ and 3′ of the target nucleic acid sequence.
  • a homologous recombination event is stimulated between the target nucleic acid sequence and the exogenous nucleic acid.
  • homologous sequences of at least 50 bp, preferably more than 100 bp and more preferably more than 200 bp are used within said donor matrix. Therefore, the exogenous nucleic acid is preferably from 200 bp to 6000 bp, more preferably from 1000 bp to 2000 bp. Indeed, shared nucleic acid homologies are located in regions flanking upstream and downstream the site of the break and the nucleic acid sequence to be introduced should be located between the two arms.
  • the gene inactivation is preferably performed by using a TAL-nuclease, meganuclease, zing-finger nuclease (ZFN), or RNA/DNA guided endonuclease, such as Cas9, Cpf1 or Argonaute.
  • TAL-nuclease TAL-nuclease
  • meganuclease TAL-nuclease
  • ZFN zing-finger nuclease
  • RNA/DNA guided endonuclease such as Cas9, Cpf1 or Argonaute.
  • the inactivation of said gene involved in the self and non-self antigen recognition is performed by using TALE-nucleases.
  • TALE-nucleases This can be accomplished at a precise genomic location targeted by a specific TALE-nuclease, wherein said specific TALE-nuclease catalyzes a cleavage and wherein said exogenous nucleic acid successively comprising at least a region of homology and a sequence to inactivate one targeted gene selected from the group previously cited.
  • TALE-nucleases can be, successively or at the same time, inactivated by using several TALE-nucleases respectively and specifically targeting one defined gene and several specific.
  • TALE-nuclease is intended a fusion protein consisting of a DNA-binding domain derived from a Transcription Activator Like Effector (TALE) and one nuclease catalytic domain to cleave a nucleic acid target sequence.
  • TALE Transcription Activator Like Effector
  • the inactivation of said gene involved in the self and non-self antigen recognition is performed by RNA-guided endonuclease such as Cas9 or DNA-guided endonuclease, such as Argonaute based techniques as described in WO2014189628.
  • RNA-guided endonuclease such as Cas9
  • DNA-guided endonuclease such as Argonaute based techniques as described in WO2014189628.
  • the present invention relates to a method to increase the persistence and/or the engraftment of allogeneic cells which comprises a step of inactivation of at least one gene involved in the self/non-self recognition.
  • gene involved in self/non-self recognition is meant a gene encoding a polypeptide that is structurally part of an external receptor or ligand, which is deemed necessary for the detection and destruction of allogeneic cells by the immune system.
  • Such genes preferably code for at least one component of TCR, MHC, in particular class I MHC, beta-2 microglobulin (B2M), TAP1 or large multifunctional protease 2.
  • the gene to be inactivated is TCR or B2M, more preferably TCR.
  • TALE-nucleases have been designed for precisely targeting relevant genes for adoptive immunotherapy strategies.
  • Preferred TALE-nucleases according to the invention are those recognizing and cleaving the target sequence selected from the group consisting of SEQ ID NO: 2-3, 5-6 and 8-9 for inactivation of ⁇ 2m and SEQ ID NO 52-53, 55-56, 62-63 and 65-66. (TCR).
  • TALE-nucleases mRNA encoding the TALE-nucleases targeting exons of the human ⁇ 2m gene were ordered from Cellectis Bioresearch (8, rue de la Croix Jarry, 75013 PARIS). Table 1 below indicates the target sequences cleaved by each of the two independent entities (called half TALE-nucleases) each containing a repeat sequence engineered to bind and cleave between target sequences consisting of two 17-bp long sequences (called half targets) separated by a 15-bp spacer.
  • PD-1 corresponds to the human Programmed Death 1 (also known as PDCD1 or CD279, RefSeq accession number: NM_005018 for the human gene).
  • This PD-1 inhibition preferably by TALEN-mediated disruption, has the objective to render allogeneic immune cells resistant to their self or reciprocal inhibition by PD-L1 (also known as CD274 or B7 homolog 1 (B7-H1), and has RefSeq No. NM_001267706 for human gene).
  • said inactivation of PD-1 gene is performed by using a polynucleotide encoding TALE-nucleases as presented in the following Table 2.
  • said step c) of the method is performed by the expression in said immune cells of at least one non-endogenous polynucleotide encoding for PD-L1 ligand bound to the membrane, and a further modification of said allogeneic cells is performed by an inactivation of the expression of PD-1 gene.
  • said step c) is performed by the expression in said immune cells at least one non-endogenous polynucleotide corresponding to secreted CTLA4 immunoglobulins, and a further modification of said allogeneic cells is performed by an inactivation of the expression of a gene encoding PD-1.
  • said step c) is performed by the step c) is performed by the expression in said immune cells of both non-endogenous immunosuppressive polypeptide PD-L1 ligand and CTLA-4 immunoglobulins, and a further modification of said allogeneic immune cells is performed by an inactivation of the expression of a gene encoding PD-1.
  • said step c) of the method of the invention is performed by the expression in said immune cells of at least one non-endogenous polynucleotide encoding for one non-endogenous immunosuppressive polypeptide bound to the membrane of said immune cells.
  • said non endogenous immunosuppressive polypeptide is present under a membrane-bound form and/or under a secreted form.
  • non-endogenous polypeptide is meant a polypeptide not normally expressed by a donor's immune cell, preferably a polypeptide expressed by an exogenous polynucleotide that has been imported into the immune's cell genome.
  • IL12 is not considered hereby as being a non-endogenous polypeptide because it is expressed from a preexisting gene from the donor's immune cell.
  • not naturally expressed is meant that the polynucleotide sequence encoding said polypeptide is either not originally present in the genome of the immune cell (e.g.: CTLA4 Ig), or said polynucleotide sequence is present in the genome but the polypeptide is expressed in the native immune cell (i.e. non-engineered) at a much lower level—generally at least 50%, preferably at least 75%, more preferably at least 100% and even more preferably 200% lower than the expression level observed into the engineered immune cell in the same experimental or treatment conditions.
  • immunosuppressive is meant that the expression of said non-endogenous polypeptide has the effect of alleviating the immune response of the patient host against the donor's immune cells.
  • said non endogenous immunosuppressive polypeptide is selected amongst PD-L1, CTLA-4-Ig, viral MHC homolog, NKG2D ligand, viral env immune suppressive domain (ISU) or the viral FP protein.
  • the method comprises as step c) an expression in immune cells at least one non-endogenous polynucleotide corresponding to a non-endogenous secreted immunosuppressive polypeptide.
  • said one non-endogenous immunosuppressive polypeptide bound to the membrane of said immune cells is a PD-L1 ligand under a membrane-bound form.
  • the non-endogenous immunosuppressive polypeptide to be expressed in said allogeneic immune cells is a ligand of CTLA-4 protein, preferably a CTLA4 immunoglobulin.
  • CTLA-4 Cytotoxic T-Lymphocyte Antigen 4
  • CD152 GenBank accession number AF414120.1
  • the polypeptide corresponding to CTLA-4 immunoglobulin to be expressed in said allogeneic immune cells comprises SEQ ID NO: 16 (CTLA-4a) or SEQ ID NO:17 (CTLA4b), or shares at least 80%, preferably 90% and more preferably 95% identity with SEQ ID NO: 16 or SEQ ID NO:17.
  • FIG. 2 The interaction between the allogeneic T cell and host immune cells is schematically represented in FIG. 2 (expression of CTLA4-Ig) in regard to the situation in FIG. 1 (no expression).
  • the nucleic acid molecule encoding CTLA-4a Ig and CTLA-4b Ig to be expressed shares respectively at least 80%, preferably 90% and more preferably 95% of identity with SEQ ID NO: 16 and SEQ ID NO: 17 as presented in the following Table 3.
  • the engineered immune cells are incubated with a non-endogenous immunosuppressive polypeptide which is anti-CD80 or anti-CD86 mAbs.
  • PD-L1 (other names: CD274, Programmed cell death 1 ligand; ref. UniProt for the human polypeptide sequence Q9NZQ7) encodes a type I transmembrane protein of 290 amino acids consisting of a Ig V-like domain, a Ig C-like domain, a hydrophobic transmembrane domain and a cytoplasmic tail of 30 amino acids.
  • the non-endogenous immunosuppressive polypeptide to be expressed in said allogeneic immune cells is a ligand of PD-L1, more especially under a membrane-bound form.
  • Such membrane-bound form of PD-L1 ligand is meant in the present invention under a native form (wild-type) or under a truncated form such as, for instance, by removing the intracellular domain, or with one or more mutation(s) (Wang S et al, 2003, J Exp Med. 2003; 197(9): 1083-1091).
  • PD1 is not considered as being a membrane-bound form of PD-L1 ligand according to the present invention.
  • the nucleic acid molecule encoding PD-L1 ligand under a membrane-bound form to be expressed is of SEQ ID NO:18, or shares at least 80%, preferably 90% and more preferably 95% of identity with SEQ ID NO:18 (corresponding to the wild-type form of PDL1-ligand).
  • said at least one non-endogenous immunosuppressive polypeptide is PD-L1 ligand under a secreted form.
  • PD-L1 secreted PD-L1
  • soluble PD-L1 may be generated by fusing the extracellular domain of PD-L1 to the Fc portion of immunoglobuline (Haile S T et al, 2014, Cancer Immunol Res. 2(7): 610-615; Song M Y et al, 2015, Gut. 64(2):260-71).
  • This recombinant PD-L1 neutralizes PD-1 and abrogates PD-1-mediated T-cell inhibition.
  • FIG. 3 The interaction between the allogeneic T cell and host immune cells is schematically represented in FIG. 3 (expression of membrane-bound PD-L1) in regard to the situation to FIG. 1 (no expression).
  • FIG. 3 represents also the situation when the PD-1 gene is disrupted by KO.
  • the non-endogenous immunosuppressive polypeptide to be expressed in said allogeneic immune cells is a PD-L1 ligand under a secreted form.
  • the interaction between the allogeneic T cell and host immune cells is schematically represented in FIG. 4 (expression of secreted PD-L1 ligand) in regard to the situation to FIG. 1 (no expression).
  • FIG. 4 represents also the situation when the PD-1 gene is disrupted by KO.
  • the nucleic acid molecule encodes formembrane-bound PD-L1 to be expressed which is of SEQ ID NO: 18, or shares at least 80%, preferably 90% and more preferably 95% of identity with SEQ ID NO: 18.
  • the present invention relates also to a method to increase the persistence and/or the engraftment of allogeneic immune cells in presence of host immune cells, wherein step c) is performed by contacting said host immune cells with both non-endogenous immunosuppressive polypeptide PD-L1 ligand and CTLA-4 immunoglobulins.
  • step c) of the method is performed by the step c) is performed by the expression in said immune cells of both non-endogenous immunosuppressive polypeptide PD-L1 ligand and CTLA-4 immunoglobulins.
  • the nucleic acid molecules encode for PD-L1 ligand under a membrane-bound form and for CTLA-4 immunoglobulins to be expressed during step c) of the method in said allogeneic immune cells, said PD-L1 ligand and CTLA-4 Ig having respectively SEQ ID NO:18 and SEQ ID NO: 16-17, or sharing at least 80%, preferably 90% and more preferably 95% of identity with respectively SEQ ID NO:18 and SEQ ID NO: 16-17.
  • the non-endogenous immunosuppressive polypeptide to be expressed in said allogeneic immune cells is a viral env immusuppressive domain (ISU), which is derived for instance from HIV-1, HIV-2, SIV, MoMuLV, HTLV-I, -II, MPMV, SRV-1, Syncitin 1 or 2, HERV-K or FELV.
  • ISU viral env immusuppressive domain
  • FIG. 5 expression of viral ISU domain
  • FIG. 1 no expression
  • Table 4 shows variants of ISU domain from diverse virus which can be expressed within the present invention.
  • the non-endogenous immunosuppressive polypeptide to be expressed in said allogeneic immune cells is an ISU domain of SEQ ID NO.19-38.
  • the non-endogenous immunosuppressive polypeptide to be expressed in said allogeneic immune cells is a viral MHC homolog, such as for instance UL18.
  • said non-endogenous immunosuppressive polypeptide is a MHC homolog comprising a chimeric beta2m-UL18 of SEQ ID NO.39, or sharing at least 80%, preferably 90% and more preferably 95% of identity with respectively SEQ ID NO:39.
  • FIG. 7 The interaction between the allogeneic T cell and host immune cells is schematically represented in FIG. 7 (expression of viral MHC homolog) in regard to the situation to FIG. 6 (no expression).
  • the MHC class I is inactivated by disrupting (KO) the beta2M gene.
  • Some viruses such as cytomegaloviruses have acquired mechanisms to avoid NK cell mediate immune surveillance and interfere with the NKG2D pathway by secreting a protein able to bind NKG2D ligands and prevent their surface expression (Welte, S. A.; Sinzger, C.; Lutz, S. Z.; Singh-Jasuja, H.; Sampaio, K. L.; Eknigk, U.; Rammensee, H. G.; Steinle, A. 2003 “Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein”. Eur. J. Immunol., 33, 194-203).
  • NKG2D ligands such as ULBP2, MICB or MICA (Salih H R, Antropius H, Gieseke F, Lutz S Z, Kanz L, et al. (2003) Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 102: 1389-1396)
  • the non-endogenous immunosuppressive polypeptide to be expressed in said allogeneic immune cells is an NKG2D ligand.
  • the interaction between the allogeneic T cell and host immune cells is schematically represented in FIG. 8 (expression of soluble NKG2D ligand) in regard to the situation to FIG. 6 (no expression).
  • the MHC class I is inactivated by disrupting (KO) the beta2M gene.
  • Table 5 represents a viral MHC homolog (UL18) and a panel of NKG2D ligands and their polypeptide sequence to be expressed according to the present invention.
  • said non-endogenous immunosuppressive polypeptide to be expressed in engineered immune cells comprises or consists of a NKG2D ligand of SEQ ID NO.40-47, or sharing at least 80%, preferably 90% and more preferably 95% of identity with respectively SEQ ID NO:40-47.
  • the non-endogenous immunosuppressive polypeptide to be expressed in said allogeneic immune cells is a FP polypeptide such as gp41.
  • the following Table 6 represents several FP polypeptide from natural and artificial origins.
  • said non-endogenous immunosuppressive polypeptide to be expressed in engineered immune cells is a FP polypeptide comprising or consisting of SEQ ID NO.48-50, or sharing at least 80%, preferably 90% and more preferably 95% of identity with respectively SEQ ID NO:48-50.
  • the inventors present here a method for increasing the persistence and/or the engraftment to apply on allogeneic immune cells, wherein a series of genetic modifications may be performed. Amongst those, are encompassed diverse combinations of both at least one inactivation gene involved in the self/non self-recognition and at least one expression of non-endogenous immunosuppressive polypeptide.
  • the genetic modifications are performed by the inactivation of the B2M and/or TCR gene combined with the expression in said allogeneic immune cells of PD-L1 ligand and/or CTLA-4 immunoglobulins and/or viral env immune suppressive domain (ISU) and/or viral FP protein and/or NKG2G ligand viral MHC homolog such as for instance UL18.
  • ISU immune env immune suppressive domain
  • polynucleotides are also comprised in the scope of the present invention, polynucleotides, vectors encoding the above described rare-cutting endonucleases according to the invention.
  • isolated cells or cell lines susceptible to be obtained by said method to engineer cells, in particular allogeneic immune cells such as T cells, in which at least one endogenous gene encoding a polypeptide involved in the self and non-self antigen recognition is inactivated and at least one non-endogenous immunosuppressive polypeptide is allowed to contact said all allogeneic immune cells.
  • allogeneic immune cells such as T cells
  • the present invention relates to a method of engineering immune cells such as T-cells, especially for immunotherapy.
  • the method comprises:
  • the present invention relates to a method of engineering immune cells such as T-cells, especially for immunotherapy.
  • the method comprises:
  • T cell-mediated immunity includes multiple sequential steps involving the clonal selection of antigen specific cells, their activation and proliferation in secondary lymphoid tissue, their trafficking to sites of antigen and inflammation, the execution of direct effector function and the provision of help (through cytokines and membrane ligands) for a multitude of effector immune cells. Each of these steps is regulated by counterbalancing stimulatory and inhibitory signal that fine-tunes the response.
  • CTLA-4 is a cell-surface protein expressed on certain CD4 and CD8 T cells; when engaged by its ligands (B7-1 and B7-2) on antigen presenting cells, T-cell activation and effector function are inhibited.
  • the present invention relates to a method of engineering T-cells, especially for immunotherapy, comprising genetically modifying T-cells by inactivating at least one protein involved in the immune check-point, in particular PD1 and/or CTLA-4.
  • the genetic modification step of the method relies on the inactivation of more than two genes.
  • the genetic modification is preferably operated ex-vivo.
  • TALE-Nucleases Cleaving Human TCR Genes (TRAC and TRBC)
  • the human genome contains two functional T-cell receptor beta chains (TRBC1 and TRBC2). During the development of alpha/beta T lymphocytes, one of these two constant chains is selected in each cell to be spliced to the variable region of TCR-beta and form a functional full length beta chain.
  • TRBC1 and TRBC2 T-cell receptor beta chains
  • the 2 TRBC targets were chosen in sequences conserved between TRBC1 and TRBC2 so that the corresponding TALE-nuclease would cleave both TRBC1 and TRBC2 at the same time.
  • Table 7 presents nucleotide sequences for 5 TRAC and 2 TRBC targets and some of their corresponding left and right TALEN. Additional sequences can be found in the applications WO2014/184741 and WO2014/184744.
  • the method comprises the step of introducing into said T-cell an exogenous nucleic acid molecule comprising a nucleotide sequence coding for a Chimeric Antigen Receptor (CAR) directed against at least one antigen expressed at the surface of a malignant or infected cell.
  • CAR Chimeric Antigen Receptor
  • They may be designed according to single-chain or multi-chain architectures.
  • the Chimeric Antigen Receptor is a single-chain CAR.
  • said extracellular ligand-binding domain is a scFv.
  • Other binding domain than scFv can also be used for predefined targeting of lymphocytes, such as camelid single-domain antibody fragments or receptor ligands like a vascular endothelial growth factor polypeptide, an integrin-binding peptide, heregulin or an IL-13 mutein, antibody binding domains, antibody hypervariable loops or CDRs as non limiting examples.
  • VH and VL chains have as antigenic target sequence of over 80% identity, preferably over 90%, and more preferably over 95% with SEQ ID NO 67 (CD19 antigen), SEQ ID NO 68 (CD38 antigen), SEQ ID NO 69 (CD123 antigen), SEQ ID NO 70 (CS1 antigen), SEQ ID NO 71 (BCMA antigen), SEQ ID NO 72 (FLT-3 antigen), SEQ ID NO 73 (CD33 antigen), SEQ ID NO 74 (CD70 antigen), SEQ ID NO 75 (EGFR-3v antigen) and SEQ ID NO 76 (WT1 antigen).
  • Other examples of surface antigens of tumoral cells to be targeted are CLL1, Hsp70, CD22, MUC16, PRAME, TSPAN10, ROR1, GD3, CT83 and mesothelin.
  • the present invention relates to a method as described above, wherein step c) is performed by the step c) is performed by the expression in said allogeneic immune cells of non-endogenous immunosuppressive polypeptide PD-L1 ligand and/or CTLA-4 immunoglobulins, said allogeneic immune cells being further modified by the expression of an anti-CD123 Chimeric Antigen Receptor.
  • said anti-CD123 CAR/PD-L1 ligand/CTLA-4 Ig expressed allogeneic immune cells are further modified during step c) of the method to undergo an inactivation of the expression of the PD-1 gene.
  • Said polypeptide of a) further may comprise a stalk region between said extracellular ligand-binding domain and said transmembrane domain.
  • the term “stalk region” used herein generally means any oligo- or polypeptide that functions to link the transmembrane domain to the extracellular ligand-binding domain. In particular, stalk region are used to provide more flexibility and accessibility for the extracellular ligand-binding domain.
  • a stalk region may comprise up to 300 amino acids, preferably 10 to 100 amino acids and most preferably 25 to 50 amino acids.
  • Stalk region may be derived from all or part of naturally occurring molecules, such as from all or part of the extracellular region of CD8, CD4 or CD28, or from all or part of an antibody constant region. Alternatively the stalk region may be a synthetic sequence that corresponds to a naturally occurring stalk sequence, or may be an entirely synthetic stalk sequence.
  • Said polypeptide may further comprise at least one signal-transducing domain.
  • said signal-transducing domain is selected from the group consisting of CD28, OX40, ICOS, CD137 and CD8.
  • Said C-terminal cytoplasmic tail of FcERI alpha, beta and/or gamma chain fragment further comprises TNFR-associated Factor 2 (TRAF2) binding motifs.
  • said C-terminal cytoplasmic tail of FcERI alpha, beta and/or gamma chain is replaced by intracytoplasmic tail of costimulatory TNFR member family.
  • Cytoplasmic tail of costimulatory TNFR family member contains TRAF2 binding motifs consisting of the major conserved motif (P/S/A)X(Q/E)E) or the minor motif (PXQXXD), wherein X is any amino acid.
  • TRAF proteins are recruited to the intracellular tails of many TNFRs in response to receptor trimerization.
  • intracytoplasmic domain of FcERI alpha, beta and/or gamma chain is replaced by intracytoplasmic domain of TCR zeta chain (also named CD3 zeta).
  • said intracytoplasmic domain of FcERI alpha, beta and/or gamma chain comprises at least one additional immunoreceptor tyrosine-based activation motif (ITAM).
  • ITAMs are well defined signaling motifs found in the intracytoplasmic tail of a variety of receptors that serve as binding sites for syk/zap70 class tyrosine kinases.
  • ITAM used in the invention examples include those derived from TCRzeta, FCRgamma, FCRbeta, CD3gamma, CD3delta, CD3epsilon, CD5, CD22, CD79a, CD79b, and CD66d.
  • SEQ ID NO: 77 an example of single-chain CAR is depicted by the SEQ ID NO: 77.
  • said above CAR is single-chain CAR chosen in the group consisting of anti-CD123 single-chain CAR, anti-CS1 single-chain CAR, anti-CD38 single-chain CAR, anti-CLL1 single-chain CAR, anti-Hsp70 single-chain CAR, anti-EGFRvIll single-chain CAR, anti-BCMA single-chain CAR, anti-CD33 single-chain CAR, anti-FLT3 single-chain CAR, anti-CD70 single-chain CAR, anti-WT1 single-chain CAR, anti-MUC16 single-chain CAR, anti-PRAME single-chain CAR, anti-TSPAN10 single-chain CAR, anti-ROR1 single-chain CAR, anti-GD3 single-chain CAR, anti-CT83 single-chain CAR and mesothelin single-chain CAR;
  • transmembrane domain i.e CD8 ⁇ TM
  • co-stimulatory domain ie. 4-1BB
  • hinge CD8alpha, FcERlllgamma, IgG1
  • cytoplasmic signaling domain ITAM CD3zeta
  • VH and VL may be those described in the applications WO2015140268 for anti-CD123, WO2015121454 for anti-CS1 and anti-CD38.
  • the invention relates to a multi-chain chimeric antigen receptor (CAR) particularly adapted to the production and expansion of engineered immune cells such as T-cells of the present invention.
  • CAR chimeric antigen receptor
  • the multi-chain CAR comprising at least two of the following components:
  • polypeptides comprising each a part of intracytoplasmic tail and the transmembrane domain of FcERI gamma chain, whereby different polypeptides multimerize together spontaneously to form dimeric, trimeric or tetrameric CAR.
  • CAR of the present invention can also be “multi-chain CARs” as previously mentioned, which means that the extracellular binding domain and the signaling domains are preferably located on different polypeptide chains, whereas co-stimulatory domains may be located on the same or a third polypeptide.
  • Such multi-chain CARs can be derived from FcERI (Ravetch et al, 1989), by replacing the high affinity IgE binding domain of FcERI alpha chain by an extracellular ligand-binding domain such as scFv, whereas the N and/or C-termini tails of FcERI beta and/or gamma chains are fused to signal transducing domains and co-stimulatory domains respectively.
  • the extracellular ligand binding domain has the role of redirecting T-cell specificity towards cell targets, while the signal transducing domains activate or reduce the immune cell response.
  • the fact that the different polypeptides derive from the alpha, beta and gamma polypeptides from FcERI are transmembrane polypeptides sitting in juxtamembrane position provides a more flexible architecture to CARs, improving specificity towards the targeted molecule and reducing background activation of immune cells. Multi-chain architectures are more particularly disclosed in WO2014039523.
  • said CAR which are expressed in the immune cell such as described earlier is chosen in the group consisting of anti-CD123 multi-chain CAR, anti-CS1 multi-chain CAR, anti-CD38 multi-chain CAR, anti-CLL1 multi-chain CAR or anti-Hsp70 multi-chain CAR.
  • said above CAR is multi-chain CAR chosen in the group consisting of anti-CD123 multi-chain CAR, anti-CS1 multi-chain CAR, anti-CD38 multi-chain CAR, anti-CLL1 multi-chain CAR, anti-Hsp70 multi-chain CAR, anti-EGFRvIll multi-chain CAR, anti-BCMA multi-chain CAR, anti-CD33 multi-chain CAR, anti-FLT3 multi-chain CAR, anti-CD70 multi-chain CAR, anti-WT1 multi-chain CAR, anti-MUC16 multi-chain CAR, anti-PRAME multi-chain CAR, anti-TSPAN10 multi-chain CAR, anti-ROR1 multi-chain CAR, anti-GD3 multi-chain CAR, anti-CT83 multi-chain CAR and mesothelin multi-chain CAR.
  • Such multi-chain CAR architectures are disclosed in WO2014/039523, especially in FIGS. 2 to 4 , and from page 14 to 21, which are herein incorporated by reference.
  • amino acid sequence functional variants of the polypeptide can be prepared by mutations in the DNA which encodes the polypeptide.
  • Such functional variants include, for example, deletions from, or insertions or substitutions of, residues within the amino acid sequence. Any combination of deletion, insertion, and substitution may also be made to arrive at the final construct, provided that the final construct possesses the desired activity, especially to exhibit a specific anti-target cellular immune activity.
  • polynucleotides are also comprised in the scope of the present invention, polynucleotides, vectors encoding the above described multi-chain CAR according to the invention.
  • the invention relates to a method of preparing immune cells such as T-cells for immunotherapy comprising introducing into said T-cells the different polypeptides composing said multi-chain CAR and expanding said cells.
  • the present invention also relates isolated cells or cell lines susceptible to be obtained by said method to engineer cells.
  • said isolated cell comprises exogenous polynucleotide sequences encoding polypeptides composing said multi-chain CAR.
  • engineered immune cells such as T cells obtained by the different methods as previously described can be further exposed with bispecific antibodies.
  • Said T-cells could be exposed to bispecific antibodies ex vivo prior to administration to a patient or in vivo following administration to a patient.
  • Said bispecific antibodies comprise two variable regions with distinct antigen properties that allow bringing the engineered cells into proximity to a target antigen.
  • said bispecific antibody is directed against a tumor marker and lymphocyte antigen such as CD3 and has the potential to redirect and activate any circulating T cells against tumors.
  • the different methods described above involve introducing pTalpha or functional variants thereof, rare cutting endonuclease, TALE-nuclease, CAR or multi-chain CAR optionally with DNA-end processing enzyme or exogenous nucleic acid into a cell.
  • rare cutting endonucleases TALE-nucleases, gene encoding non-endogenous immunosuppressive polypeptide, CAR or multi-chain CAR optionally with DNA-end processing enzyme or exogenous nucleic acid can be introduced as transgenes encoded by one or as different plasmidic vectors.
  • Different transgenes can be included in one vector which comprises a nucleic acid sequence encoding ribosomal skip sequence such as a sequence encoding a 2A peptide.
  • 2A peptides which were identified in the Aphthovirus subgroup of picornaviruses, causes a ribosomal “skip” from one codon to the next without the formation of a peptide bond between the two amino acids encoded by the codons (see Donnelly et al., J. of General Virology 82: 1013-1025 (2001); Donnelly et al., J. of Gen. Virology 78: 13-21 (1997); Doronina et al., Mol. And. Cell. Biology 28(13): 4227-4239 (2008); Atkins et al., RNA 13: 803-810 (2007)).
  • codon is meant three nucleotides on an mRNA (or on the sense strand of a DNA molecule) that are translated by a ribosome into one amino acid residue.
  • two polypeptides can be synthesized from a single, contiguous open reading frame within an mRNA when the polypeptides are separated by a 2A oligopeptide sequence that is in frame.
  • Such ribosomal skip mechanisms are well known in the art and are known to be used by several vectors for the expression of several proteins encoded by a single messenger RNA.
  • 2A peptides have been used to express into the cell the rare-cutting endonuclease and a DNA end-processing enzyme or the different polypeptides of the multi-chain CAR.
  • Said plasmid vector can contain a selection marker which provides for identification and/or selection of cells which received said vector.
  • Polypeptides may be synthesized in situ in the cell as a result of the introduction of polynucleotides encoding said polypeptides into the cell. Alternatively, said polypeptides could be produced outside the cell and then introduced thereto.
  • Methods for introducing a polynucleotide construct into animal cells are known in the art and including as non-limiting examples stable transformation methods wherein the polynucleotide construct is integrated into the genome of the cell, transient transformation methods wherein the polynucleotide construct is not integrated into the genome of the cell and virus mediated methods.
  • Said polynucleotides may be introduced into a cell by for example, recombinant viral vectors (e.g.
  • retroviruses adenoviruses
  • liposome adenoviruses
  • transient transformation methods include for example microinjection, electroporation or particle bombardment.
  • Said polynucleotides may be included in vectors, more particularly plasmids or virus, in view of being expressed in cells.
  • Polynucleotides encoding polypeptides according to the present invention can be mRNA which is introduced directly into the cells, for example by electroporation.
  • the inventors determined the optimal condition for mRNA electroporation in T-cell.
  • the inventor used the cytoPulse technology which allows, by the use of pulsed electric fields, to transiently permeabilize living cells for delivery of material into the cells.
  • the technology based on the use of PulseAgile (Cellectis property) electroporation waveforms grants the precise control of pulse duration, intensity as well as the interval between pulses (U.S. Pat. No. 6,010,613 and International PCT application WO2004083379). All these parameters can be modified in order to reach the best conditions for high transfection efficiency with minimal mortality.
  • the first high electric field pulses allow pore formation, while subsequent lower electric field pulses allow to move the polynucleotide into the cell.
  • the inventor describe the steps that led to achievement of >95% transfection efficiency of mRNA in T cells, and the use of the electroporation protocol to transiently express different kind of proteins in T cells.
  • the invention relates to a method of transforming T cell comprising contacting said T cell with RNA and applying to T cell an agile pulse sequence consisting of:
  • step (a) one electrical pulse with a voltage range from 2250 to 3000 V per centimeter, a pulse width of 0.1 ms and a pulse interval of 0.2 to 10 ms between the electrical pulses of step (a) and (b);
  • step (b) one electrical pulse with a voltage range from 2250 to 3000 V with a pulse width of 100 ms and a pulse interval of 100 ms between the electrical pulse of step (b) and the first electrical pulse of step (c);
  • the method of transforming T cell may comprise contacting said T cell with RNA and applying to T cell an agile pulse sequence consisting of:
  • step (a) one electrical pulse with a voltage of 2250, 2300, 2350, 2400, 2450, 2500, 2550, 2400, 2450, 2500, 2600, 2700, 2800, 2900 or 3000V per centimeter, a pulse width of 0.1 ms and a pulse interval of 0.2, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 ms between the electrical pulses of step (a) and (b);
  • step (b) one electrical pulse with a voltage range from 2250, of 2250, 2300, 2350, 2400, 2450, 2500, 2550, 2400, 2450, 2500, 2600, 2700, 2800, 2900 or 3000V with a pulse width of 100 ms and a pulse interval of 100 ms between the electrical pulse of step (b) and the first electrical pulse of step (c); and
  • Electroporation medium can be any suitable medium known in the art.
  • the electroporation medium has conductivity in a range spanning 0.01 to 1.0 milliSiemens.
  • said RNA encodes a rare-cutting endonuclase, one monomer of the rare-cutting endonuclease such as Half-TALE-nuclease, a Chimeric Antigen Receptor, at least one component of the multi-chain chimeric antigen receptor, an exogenous nucleic acid, one additional catalytic domain.
  • a rare-cutting endonuclase one monomer of the rare-cutting endonuclease such as Half-TALE-nuclease, a Chimeric Antigen Receptor, at least one component of the multi-chain chimeric antigen receptor, an exogenous nucleic acid, one additional catalytic domain.
  • the immune cells can be activated and expanded generally using methods as described, for example, in U.S. Pat. Nos. 6,352,694; 6,534,055; 6,905,680; 6,692,964; 5,858,358; 6,887,466; 6,905,681; 7,144,575; 7,067,318; 7,172,869; 7,232,566; 7,175,843; 5,883,223; 6,905,874; 6,797,514; 6,867,041; and U.S. Patent Application Publication No. 20060121005.
  • T cells can be expanded in vitro or in vivo.
  • the T cells of the invention are expanded by contact with a surface having attached thereto an agent that stimulates a CD3 TCR complex associated signal and a ligand that stimulates a co-stimulatory molecule on the surface of the T cells.
  • immune cells such as T cell populations may be stimulated in vitro such as by contact with an anti-CD3 antibody, or antigen-binding fragment thereof, or an anti-CD2 antibody immobilized on a surface, or by contact with a protein kinase C activator (e.g., bryostatin) in conjunction with a calcium ionophore.
  • a protein kinase C activator e.g., bryostatin
  • a ligand that binds the accessory molecule is used for co-stimulation of an accessory molecule on the surface of the T cells.
  • a population of immune cells can be contacted with an anti-CD3 antibody and an anti-CD28 antibody, under conditions appropriate for stimulating proliferation of the immune cells.
  • an anti-CD3 antibody and an anti-CD28 antibody may be in solution or coupled to a surface.
  • the ratio of particles to cells may depend on particle size relative to the target cell.
  • the cells such as T cells
  • the agents providing each signal may be in solution or coupled to a surface.
  • the ratio of particles to cells may depend on particle size relative to the target cell.
  • the cells such as T cells
  • the agents-coated beads and cells are subsequently separated, and then the cells are cultured.
  • the agent-coated beads and cells prior to culture, are not separated but are cultured together.
  • Cell surface proteins may be ligated by allowing paramagnetic beads to which anti-CD3 and anti-CD28 are attached (3 ⁇ 28 beads) to contact the T cells.
  • the cells for example, 4 to 10 T cells
  • beads for example, DYNABEADS® M-450 CD3/CD28 T paramagnetic beads at a ratio of 1:1
  • a buffer preferably PBS (without divalent cations such as, calcium and magnesium).
  • PBS without divalent cations such as, calcium and magnesium
  • any cell concentration may be used.
  • the mixture may be cultured for several hours (about 3 hours) to about 14 days or any hourly integer value in between. In another embodiment, the mixture may be cultured for 21 days.
  • Conditions appropriate for T cell culture include an appropriate media (e.g., Minimal Essential Media or RPMI Media 1640 or, X-vivo 5, (Lonza)) that may contain factors necessary for proliferation and viability, including serum (e.g., fetal bovine or human serum), interleukin-2 (IL-2), insulin, IFN-g, 1L-4, 1L-7, GM-CSF, -10, -2, 1L-15, TGFp, and TNF- or any other additives for the growth of cells known to the skilled artisan.
  • Other additives for the growth of cells include, but are not limited to, surfactant, plasmanate, and reducing agents such as N-acetyl-cysteine and 2-mercaptoethanoi.
  • Media can include RPMI 1640, A1M-V, DMEM, MEM, a-MEM, F-12, X-Vivo 1, and X-Vivo 20, Optimizer, with added amino acids, sodium pyruvate, and vitamins, either serum-free or supplemented with an appropriate amount of serum (or plasma) or a defined set of hormones, and/or an amount of cytokine(s) sufficient for the growth and expansion of T cells.
  • Antibiotics e.g., penicillin and streptomycin, are included only in experimental cultures, not in cultures of cells that are to be infused into a subject.
  • the target cells are maintained under conditions necessary to support growth, for example, an appropriate temperature (e.g., 37° C.) and atmosphere (e.g., air plus 5% CO2). Immune cells such as T cells that have been exposed to varied stimulation times may exhibit different characteristics.
  • said cells can be expanded by co-culturing with tissue or cells. Said cells can also be expanded in vivo, for example in the subject's blood after administrating said cell into the subject.
  • an isolated immune cell obtained according to any one of the methods previously described.
  • Said immune cell according to the present invention can be derived from a hematopoietic stem cell.
  • the stem cells can be adult stem cells, embryonic stem cells, more particularly non-human stem cells, cord blood stem cells, progenitor cells, bone marrow stem cells, induced pluripotent stem cells, totipotent stem cells or hematopoietic stem cells.
  • said immune cells are hematopoietic cells, and more preferably primary cells.
  • the engineered allogeneic immune cells after contacting at least one non-endogenous immunosuppressive polypeptide, do not induce specifically the inhibition of T regulatory cells.
  • the engineered allogeneic immune cells after contacting at least one non-endogenous immunosuppressive polypeptide, induce specifically an inhibition of CD8+ T cells.
  • a source of cells can be obtained from a subject through a variety of non-limiting methods.
  • Immune cells such as T cells can be obtained from a number of non-limiting sources, including peripheral blood mononuclear cells, bone marrow, lymph node tissue, cord blood, thymus tissue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, and tumors. Any number of immune cell lines available and known to those skilled in the art, may be used.
  • said cell can be derived from a healthy donor, from a patient diagnosed with cancer or from a patient diagnosed with an infection. Said cell is part of a mixed population of cells which present different phenotypic characteristics.
  • a cell line obtained from a transformed immune cell such as T-cell is also encompassed a cell line obtained from a transformed immune cell such as T-cell according to the method previously described. Modified cells resistant to an immunosuppressive treatment and susceptible to be obtained by the previous method are encompassed in the scope of the present invention.
  • said isolated cell according to the present invention comprises one inactivated endogenous gene encoding a polypeptide involved in the self and non-self antigen recognition, such as TCR, MHC class of class I component, b-2 microglobulin (B2M), TAP1 and large multifunctional protease 2.
  • said engineered allogeneic immune cells are contacted with at least one non-endogenous immunosuppressive polypeptide, either by expressing at least one secreted non-endogenous immunosuppressive polypeptide or by incubating said immune cells with at least one non-endogenous immunosuppressive polypeptide.
  • isolated cell obtained by the different methods or cell line derived from said isolated cell as previously described can be used as a medicament.
  • said medicament can be used for treating cancer or infections in a patient in need thereof.
  • said isolated cell according to the invention or cell line derived from said isolated cell can be used in the manufacture of a medicament for treatment of a cancer or a viral infection in a patient in need thereof.
  • the present invention relies on methods for treating patients in need thereof, said method comprising at least one of the following steps:
  • said immune cell such as T cells of the invention can undergo robust in vivo immune cell such as T cell expansion and can persist for an extended amount of time.
  • Said treatment can be ameliorating, curative or prophylactic. It may be either part of an autologous immunotherapy or part of an allogenic immunotherapy treatment.
  • autologous it is meant that cells, cell line or population of cells used for treating patients are originating from said patient or from a Human Leucocyte Antigen (HLA) compatible donor.
  • HLA Human Leucocyte Antigen
  • allogeneic is meant that the cells or population of cells used for treating patients are not originating from said patient but from a donor.
  • the invention is particularly suited for allogenic immunotherapy, insofar as it enables the transformation of immune cells such as T-cells, typically obtained from donors, into non-alloreactive cells. This may be done under standard protocols and reproduced as many times as needed.
  • the resulted modified immune cells may be pooled and administrated to one or several patients, being made available as an “off the shelf” therapeutic product.
  • Cancers that can be used with the disclosed methods are described in the previous section. Said treatment can be used to treat patients diagnosed with cancer, viral infection, autoimmune disorders or Graft versus Host Disease (GvHD). Cancers that may be treated include tumors that are not vascularized, or not yet substantially vascularized, as well as vascularized tumors.
  • the cancers may comprise nonsolid tumors (such as hematological tumors, for example, leukemias and lymphomas) or may comprise solid tumors.
  • Types of cancers to be treated with the CARs of the invention include, but are not limited to, carcinoma, blastoma, and sarcoma, and certain leukemia or lymphoid malignancies, benign and malignant tumors, and malignancies e.g., sarcomas, carcinomas, and melanomas.
  • carcinoma a malignant neoplasm originating from a malignant neoplasm originating from tumors.
  • sarcomas e.g., sarcomas, carcinomas, and melanomas.
  • adult tumors/cancers and pediatric tumors/cancers are also included.
  • It can be a treatment in combination with one or more therapies against cancer selected from the group of antibodies therapy, chemotherapy, cytokines therapy, dendritic cell therapy, gene therapy, hormone therapy, laser light therapy and radiation therapy.
  • therapies against cancer selected from the group of antibodies therapy, chemotherapy, cytokines therapy, dendritic cell therapy, gene therapy, hormone therapy, laser light therapy and radiation therapy.
  • said treatment can be administrated into patients undergoing an immunosuppressive treatment.
  • the present invention preferably relies on cells or population of cells, which have been made resistant to at least one immunosuppressive agent due to the inactivation of a gene encoding a receptor for such immunosuppressive agent.
  • the immunosuppressive treatment should help the selection and expansion of the T-cells according to the invention within the patient.
  • the administration of the cells or population of cells according to the present invention may be carried out in any convenient manner, including by aerosol inhalation, injection, ingestion, transfusion, implantation or transplantation.
  • the compositions described herein may be administered to a patient subcutaneously, intradermaliy, intratumorally, intranodally, intramedullary, intramuscularly, by intravenous or intralymphatic injection, or intraperitoneally.
  • the cell compositions of the present invention are preferably administered by intravenous injection.
  • the administration of the cells or population of cells can consist of the administration of 10 4 -10 9 cells per kg body weight, preferably 10 5 to 10 6 cells/kg body weight including all integer values of cell numbers within those ranges.
  • the cells or population of cells can be administrated in one or more doses.
  • said effective amount of cells are administrated as a single dose.
  • said effective amount of cells are administrated as more than one dose over a period time. Timing of administration is within the judgment of managing physician and depends on the clinical condition of the patient.
  • the cells or population of cells may be obtained from any source, such as a blood bank or a donor. While individual needs vary, determination of optimal ranges of effective amounts of a given cell type for a particular disease or conditions within the skill of the art.
  • An effective amount means an amount which provides a therapeutic or prophylactic benefit.
  • the dosage administrated will be dependent upon the age, health and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment and the nature of the effect desired.
  • said effective amount of cells or composition comprising those cells are administrated parenterally.
  • Said administration can be an intravenous administration.
  • Said administration can be directly done by injection within a tumor.
  • cells are administered to a patient in conjunction with (e.g., before, simultaneously or following) any number of relevant treatment modalities, including but not limited to treatment with agents such as antiviral therapy, cidofovir and interleukin-2, Cytarabine (also known as ARA-C) or nataliziimab treatment for MS patients or efaliztimab treatment for psoriasis patients or other treatments for PML patients.
  • agents such as antiviral therapy, cidofovir and interleukin-2, Cytarabine (also known as ARA-C) or nataliziimab treatment for MS patients or efaliztimab treatment for psoriasis patients or other treatments for PML patients.
  • the T cells of the invention may be used in combination with chemotherapy, radiation, immunosuppressive agents, such as cyclosporin, azathioprine, methotrexate, mycophenolate, and FK506, antibodies, or other immunoablative agents such as CAM PATH, anti-CD3 antibodies or other antibody therapies, cytoxin, fludaribine, cyclosporin, FK506, rapamycin, mycophenolic acid, steroids, FR901228, cytokines, and irradiation.
  • immunosuppressive agents such as cyclosporin, azathioprine, methotrexate, mycophenolate, and FK506, antibodies
  • immunoablative agents such as CAM PATH, anti-CD3 antibodies or other antibody therapies
  • cytoxin fludaribine
  • cyclosporin FK506, rapamycin
  • mycophenolic acid steroids
  • steroids FR901228
  • cytokines irradiation
  • the cell compositions of the present invention are administered to a patient in conjunction with (e.g., before, simultaneously or following) bone marrow transplantation, T cell ablative therapy using either chemotherapy agents such as, fludarabine, external-beam radiation therapy (XRT), cyclophosphamide, or antibodies such as OKT3 or CAMPATH,
  • chemotherapy agents such as, fludarabine, external-beam radiation therapy (XRT), cyclophosphamide, or antibodies such as OKT3 or CAMPATH
  • the cell compositions of the present invention are administered following B-cell ablative therapy such as agents that react with CD20, e.g., Rituxan.
  • subjects may undergo standard treatment with high dose chemotherapy followed by peripheral blood stem cell transplantation.
  • subjects receive an infusion of the expanded immune cells of the present invention.
  • expanded cells are administered before or following surgery.
  • Said modified cells obtained by any one of the methods described here can be used in a particular aspect of the invention for treating patients in need thereof against Host versus Graft (HvG) rejection and Graft versus Host Disease (GvHD); therefore in the scope of the present invention is a method of treating patients in need thereof against Host versus Graft (HvG) rejection and Graft versus Host Disease (GvHD) comprising treating said patient by administering to said patient an effective amount of modified cells comprising inactivated TCR alpha and/or TCR beta genes.
  • Amino acid residues in a polypeptide sequence are designated herein according to the one-letter code, in which, for example, Q means Gln or Glutamine residue, R means Arg or Arginine residue and D means Asp or Aspartic acid residue.
  • Amino acid substitution means the replacement of one amino acid residue with another, for instance the replacement of an Arginine residue with a Glutamine residue in a peptide sequence is an amino acid substitution.
  • Nucleotides are designated as follows: one-letter code is used for designating the base of a nucleoside: a is adenine, t is thymine, c is cytosine, and g is guanine.
  • r represents g or a (purine nucleotides)
  • k represents g or t
  • s represents g or c
  • w represents a or t
  • m represents a or c
  • y represents t or c (pyrimidine nucleotides)
  • d represents g, a or t
  • v represents g, a or c
  • b represents g, t or c
  • h represents a, t or c
  • n represents g, a, t or c.
  • nucleic acid or “polynucleotides” refers to nucleotides and/or polynucleotides, such as deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), oligonucleotides, fragments generated by the polymerase chain reaction (PCR), and fragments generated by any of ligation, scission, endonuclease action, and exonuclease action.
  • DNA deoxyribonucleic acid
  • RNA ribonucleic acid
  • PCR polymerase chain reaction
  • Nucleic acid molecules can be composed of monomers that are naturally-occurring nucleotides (such as DNA and RNA), or analogs of naturally-occurring nucleotides (e.g., enantiomeric forms of naturally-occurring nucleotides), or a combination of both.
  • Modified nucleotides can have alterations in sugar moieties and/or in pyrimidine or purine base moieties.
  • Sugar modifications include, for example, replacement of one or more hydroxyl groups with halogens, alkyl groups, amines, and azido groups, or sugars can be functionalized as ethers or esters.
  • sugar moiety can be replaced with sterically and electronically similar structures, such as aza-sugars and carbocyclic sugar analogs.
  • modifications in a base moiety include alkylated purines and pyrimidines, acylated purines or pyrimidines, or other well-known heterocyclic substitutes.
  • Nucleic acid monomers can be linked by phosphodiester bonds or analogs of such linkages. Nucleic acids can be either single stranded or double stranded.
  • DNA target a polynucleotide sequence that can be targeted and processed by a rare-cutting endonuclease according to the present invention.
  • These terms refer to a specific DNA location, preferably a genomic location in a cell, but also a portion of genetic material that can exist independently to the main body of genetic material such as plasmids, episomes, virus, transposons or in organelles such as mitochondria as non-limiting example.
  • TALE-nuclease targets targeted genomic sequences generally consist of two 17-bp long sequences (called half targets) separated by a 15-bp spacer.
  • Each half-target is recognized by repeats of TALE-nucleases listed in tables 2, 7 and 11 as non-limiting examples, encoded in plasmids, under the control of EF1-alpha promoter or T7 promoter.
  • the nucleic acid target sequence is defined by the 5′ to 3′ sequence of one strand of said target, as indicated in tables 2 and 7.
  • CAR chimeric antigen receptor
  • a component present on the target cell for example an antibody-based specificity for a desired antigen (e.g., tumor antigen) with a T cell receptor-activating intracellular domain to generate a chimeric protein that exhibits a specific anti-target cellular immune activity.
  • CAR consists of an extracellular single chain antibody (scFvFc) fused to the intracellular signaling domain of the T cell antigen receptor complex zeta chain (scFvFc: ⁇ ) and have the ability, when expressed in T cells, to redirect antigen recognition based on the monoclonal antibody's specificity.
  • scFvFc extracellular single chain antibody
  • scFvFc: ⁇ extracellular single chain antibody
  • scFvFc: ⁇ extracellular signaling domain of the T cell antigen receptor complex zeta chain
  • One example of CAR used in the present invention is a CAR directing against CD19 antigen and can comprise as non-limiting example the amino acid sequence
  • delivery vector or “delivery vectors” is intended any delivery vector which can be used in the present invention to put into cell contact (i.e “contacting”) or deliver inside cells or subcellular compartments (i.e “introducing”) agents/chemicals and molecules (proteins or nucleic acids) needed in the present invention. It includes, but is not limited to liposomal delivery vectors, viral delivery vectors, drug delivery vectors, chemical carriers, polymeric carriers, lipoplexes, polyplexes, dendrimers, microbubbles (ultrasound contrast agents), nanoparticles, emulsions or other appropriate transfer vectors.
  • delivery vectors allow delivery of molecules, chemicals, macromolecules (genes, proteins), or other vectors such as plasmids, peptides developed by Diatos. In these cases, delivery vectors are molecule carriers.
  • delivery vector or “delivery vectors” is also intended delivery methods to perform transfection.
  • vector refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked.
  • a “vector” in the present invention includes, but is not limited to, a viral vector, a plasmid, a RNA vector or a linear or circular DNA or RNA molecule which may consists of a chromosomal, non chromosomal, semi-synthetic or synthetic nucleic acids.
  • Preferred vectors are those capable of autonomous replication (episomal vector) and/or expression of nucleic acids to which they are linked (expression vectors). Large numbers of suitable vectors are known to those of skill in the art and commercially available.
  • Viral vectors include retrovirus, adenovirus, parvovirus (e.g. adenoassociated viruses), coronavirus, negative strand RNA viruses such as orthomyxovirus (e.g., influenza virus), rhabdovirus (e.g., rabies and vesicular stomatitis virus), paramyxovirus (e.g.
  • RNA viruses such as picornavirus and alphavirus
  • double-stranded DNA viruses including adenovirus, herpesvirus (e.g., Herpes Simplex virus types 1 and 2, Epstein-Barr virus, cytomegalovirus), and poxvirus (e.g., vaccinia, fowlpox and canarypox).
  • herpesvirus e.g., Herpes Simplex virus types 1 and 2, Epstein-Barr virus, cytomegalovirus
  • poxvirus e.g., vaccinia, fowlpox and canarypox
  • Other viruses include Norwalk virus, togavirus, flavivirus, reoviruses, papovavirus, hepadnavirus, and hepatitis virus, for example.
  • retroviruses examples include: avian leukosis-sarcoma, mammalian C-type, B-type viruses, D type viruses, HTLV-BLV group, lentivirus, spumavirus (Coffin, J. M., Retroviridae: The viruses and their replication, In Fundamental Virology, Third Edition, B. N. Fields, et al., Eds., Lippincott-Raven Publishers, Philadelphia, 1996).
  • lentiviral vector HIV-Based lentiviral vectors that are very promising for gene delivery because of their relatively large packaging capacity, reduced immunogenicity and their ability to stably transduce with high efficiency a large range of different cell types.
  • Lentiviral vectors are usually generated following transient transfection of three (packaging, envelope and transfer) or more plasmids into producer cells.
  • lentiviral vectors enter the target cell through the interaction of viral surface glycoproteins with receptors on the cell surface.
  • the viral RNA undergoes reverse transcription, which is mediated by the viral reverse transcriptase complex.
  • the product of reverse transcription is a double-stranded linear viral DNA, which is the substrate for viral integration in the DNA of infected cells.
  • integrative lentiviral vectors or LV
  • NILV non integrative lentiviral vectors
  • efficient gene delivery vectors that do not integrate the genome of a target cell through the action of the virus integrase.
  • Delivery vectors and vectors can be associated or combined with any cellular permeabilization techniques such as sonoporation or electroporation or derivatives of these techniques.
  • cell or cells any eukaryotic living cells, primary cells and cell lines derived from these organisms for in vitro cultures.
  • primary cell or “primary cells” are intended cells taken directly from living tissue (i.e. biopsy material) and established for growth in vitro, that have undergone very few population doublings and are therefore more representative of the main functional components and characteristics of tissues from which they are derived from, in comparison to continuous tumorigenic or artificially immortalized cell lines.
  • cell lines can be selected from the group consisting of CHO-K1 cells; HEK293 cells; Caco2 cells; U2-OS cells; NIH 3T3 cells; NSO cells; SP2 cells; CHO—S cells; DG44 cells; K-562 cells, U-937 cells; MRCS cells; IMR90 cells; Jurkat cells; HepG2 cells; HeLa cells; HT-1080 cells; HCT-116 cells; Hu-h7 cells; Huvec cells; Molt 4 cells.
  • All these cell lines can be modified by the method of the present invention to provide cell line models to produce, express, quantify, detect, study a gene or a protein of interest; these models can also be used to screen biologically active molecules of interest in research and production and various fields such as chemical, biofuels, therapeutics and agronomy as non-limiting examples.
  • mutant is intended the substitution, deletion, insertion of up to one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, twenty, twenty five, thirty, fourty, fifty, or more nucleotides/amino acids in a polynucleotide (cDNA, gene) or a polypeptide sequence.
  • the mutation can affect the coding sequence of a gene or its regulatory sequence. It may also affect the structure of the genomic sequence or the structure/stability of the encoded mRNA.
  • variant(s) it is intended a repeat variant, a variant, a DNA binding variant, a TALE-nuclease variant, a polypeptide variant obtained by mutation or replacement of at least one residue in the amino acid sequence of the parent molecule.
  • “functional variant” is intended a catalytically active mutant of a protein or a protein domain; such mutant may have the same activity compared to its parent protein or protein domain or additional properties, or higher or lower activity.
  • gene is meant the basic unit of heredity, consisting of a segment of DNA arranged in a linear manner along a chromosome, which codes for a specific protein or segment of protein.
  • a gene typically includes a promoter, a 5′ untranslated region, one or more coding sequences (exons), optionally introns, a 3′ untranslated region.
  • the gene may further comprise a terminator, enhancers and/or silencers.
  • locus is the specific physical location of a DNA sequence (e.g. of a gene) on a chromosome.
  • locus can refer to the specific physical location of a rare-cutting endonuclease target sequence on a chromosome.
  • Such a locus can comprise a target sequence that is recognized and/or cleaved by a rare-cutting endonuclease according to the invention.
  • the locus of interest of the present invention can not only qualify a nucleic acid sequence that exists in the main body of genetic material (i.e. in a chromosome) of a cell but also a portion of genetic material that can exist independently to said main body of genetic material such as plasmids, episomes, virus, transposons or in organelles such as mitochondria as non-limiting examples.
  • exonuclease refers to any wild-type or variant enzyme capable of catalyzing the hydrolysis (cleavage) of bonds between nucleic acids within a DNA or RNA molecule, preferably a DNA molecule. Endonucleases do not cleave the DNA or RNA molecule irrespective of its sequence, but recognize and cleave the DNA or RNA molecule at specific polynucleotide sequences, further referred to as “target sequences” or “target sites”. Endonucleases can be classified as rare-cutting endonucleases when having typically a polynucleotide recognition site greater than 12 base pairs (bp) in length, more preferably of 14-55 bp.
  • Rare-cutting endonucleases can for example be a homing endonuclease (Paques and Duchateau 2007), a chimeric Zinc-Finger nuclease (ZFN) resulting from the fusion of engineered zinc-finger domains with the catalytic domain of a restriction enzyme such as Fokl (Porteus and Carroll 2005) or a chemical endonuclease (Eisenschmidt, Lanio et al. 2005; Arimondo, Thomas et al. 2006).
  • a chemical or peptidic cleaver is conjugated either to a polymer of nucleic acids or to another DNA recognizing a specific target sequence, thereby targeting the cleavage activity to a specific sequence.
  • Chemical endonucleases also encompass synthetic nucleases like conjugates of orthophenanthroline, a DNA cleaving molecule, and triplex-forming oligonucleotides (TFOs), known to bind specific DNA sequences (Kalish and Glazer 2005). Such chemical endonucleases are comprised in the term “endonuclease” according to the present invention.
  • Rare-cutting endonucleases can also be for example TALE-nucleases, a new class of chimeric nucleases using a Fokl catalytic domain and a DNA binding domain derived from Transcription Activator Like Effector (TALE), a family of proteins used in the infection process by plant pathogens of the Xanthomonas genus (Boch, Scholze et al. 2009; Moscou and Bogdanove 2009; Christian, Cermak et al. 2010; Li, Huang et al.).
  • TALE Transcription Activator Like Effector
  • TALE-nuclease Fokl-based TALE-nuclease
  • ZFN Zinc-finger DNA binding domain
  • TALE-nuclease DNA cleavage by a TALE-nuclease requires two DNA recognition regions flanking an unspecific central region.
  • Rare-cutting endonucleases encompassed in the present invention can also be derived from TALE-nucleases.
  • Rare-cutting endonuclease can be a homing endonuclease, also known under the name of meganuclease. Such homing endonucleases are well-known to the art (Stoddard 2005). Homing endonucleases recognize a DNA target sequence and generate a single- or double-strand break. Homing endonucleases are highly specific, recognizing DNA target sites ranging from 12 to 45 base pairs (bp) in length, usually ranging from 14 to 40 bp in length.
  • the homing endonuclease according to the invention may for example correspond to a LAGLIDADG endonuclease, to a HNH endonuclease, or to a GIY-YIG endonuclease.
  • Preferred homing endonuclease according to the present invention can be an I-CreI variant.
  • TALE-nuclease a fusion protein consisting of a nucleic acid-binding domain typically derived from a Transcription Activator Like Effector (TALE) and one nuclease catalytic domain to cleave a nucleic acid target sequence.
  • the catalytic domain is preferably a nuclease domain and more preferably a domain having endonuclease activity, like for instance I-TevI, ColE7, NucA and Fok-I.
  • the TALE domain can be fused to a meganuclease like for instance I-CreI and I-OnuI or functional variant thereof.
  • said nuclease is a monomeric TALE-Nuclease.
  • a monomeric TALE-Nuclease is a TALE-Nuclease that does not require dimerization for specific recognition and cleavage, such as the fusions of engineered TAL repeats with the catalytic domain of I-TevI described in WO2012138927.
  • Transcription Activator like Effector are proteins from the bacterial species Xanthomonas comprise a plurality of repeated sequences, each repeat comprising di-residues in position 12 and 13 (RVD) that are specific to each nucleotide base of the nucleic acid targeted sequence.
  • Binding domains with similar modular base-per-base nucleic acid binding properties can also be derived from new modular proteins recently discovered by the applicant in a different bacterial species.
  • the new modular proteins have the advantage of displaying more sequence variability than TAL repeats.
  • RVDs associated with recognition of the different nucleotides are HD for recognizing C, NG for recognizing T, NI for recognizing A, NN for recognizing G or A, NS for recognizing A, C, G or T, HG for recognizing T, IG for recognizing T, NK for recognizing G, HA for recognizing C, ND for recognizing C, HI for recognizing C, HN for recognizing G, NA for recognizing G, SN for recognizing G or A and YG for recognizing T, TL for recognizing A, VT for recognizing A or G and SW for recognizing A.
  • critical amino acids 12 and 13 can be mutated towards other amino acid residues in order to modulate their specificity towards nucleotides A, T, C and G and in particular to enhance this specificity.
  • TALE-nuclease have been already described and used to stimulate gene targeting and gene modifications (Boch, Scholze et al. 2009; Moscou and Bogdanove 2009; Christian, Cermak et al. 2010; Li, Huang et al.).
  • Engineered TAL-nucleases are commercially available under the trade name TALENTM (Cellectis, 8 rue de la Croix Jarry, 75013 Paris, France).
  • cleavage refers to the breakage of the covalent backbone of a polynucleotide. Cleavage can be initiated by a variety of methods including, but not limited to, enzymatic or chemical hydrolysis of a phosphodiester bond. Both single-stranded cleavage and double-stranded cleavage are possible, and double-stranded cleavage can occur as a result of two distinct single-stranded cleavage events. Double stranded DNA, RNA, or DNA/RNA hybrid cleavage can result in the production of either blunt ends or staggered ends.
  • fusion protein is intended the result of a well-known process in the art consisting in the joining of two or more genes which originally encode for separate proteins or part of them, the translation of said “fusion gene” resulting in a single polypeptide with functional properties derived from each of the original proteins.
  • identity refers to sequence identity between two nucleic acid molecules or polypeptides. Identity can be determined by comparing a position in each sequence which may be aligned for purposes of comparison. When a position in the compared sequence is occupied by the same base, then the molecules are identical at that position. A degree of similarity or identity between nucleic acid or amino acid sequences is a function of the number of identical or matching nucleotides at positions shared by the nucleic acid sequences. Various alignment algorithms and/or programs may be used to calculate the identity between two sequences, including FASTA, or BLAST which are available as a part of the GCG sequence analysis package (University of Wisconsin, Madison, Wis.), and can be used with, e.g., default setting.
  • polypeptides having at least 70%, 85%, 90%, 95%, 98% or 99% identity to specific polypeptides described herein and preferably exhibiting substantially the same functions, as well as polynucleotide encoding such polypeptides, are contemplated.
  • similarity describes the relationship between the amino acid sequences of two or more polypeptides.
  • BLASTP may also be used to identify an amino acid sequence having at least 70%, 75%, 80%, 85%, 87.5%, 90%, 92.5%, 95%, 97.5%, 98%, 99% sequence similarity to a reference amino acid sequence using a similarity matrix such as BLOSUM45, BLOSUM62 or BLOSUM80. Unless otherwise indicated a similarity score will be based on use of BLOSUM62.
  • BLOSUM45 BLOSUM45
  • BLOSUM62 BLOSUM80
  • BLASTP “Identities” shows the number and fraction of total residues in the high scoring sequence pairs which are identical; and BLASTP “Positives” shows the number and fraction of residues for which the alignment scores have positive values and which are similar to each other.
  • Amino acid sequences having these degrees of identity or similarity or any intermediate degree of identity of similarity to the amino acid sequences disclosed herein are contemplated and encompassed by this disclosure.
  • the polynucleotide sequences of similar polypeptides are deduced using the genetic code and may be obtained by conventional means.
  • signal-transducing domain or “co-stimulatory ligand” refers to a molecule on an antigen presenting cell that specifically binds a cognate co-stimulatory molecule on a T-cell, thereby providing a signal which, in addition to the primary signal provided by, for instance, binding of a TCR/CD3 complex with an MHC molecule loaded with peptide, mediates a T cell response, including, but not limited to, proliferation activation, differentiation and the like.
  • a co-stimulatory ligand can include but is not limited to CD7, B7-1 (CD80), B7-2 (CD86), PD-L1, PD-L2, 4-1BBL, OX40L, inducible costimulatory igand (ICOS-L), intercellular adhesion molecule (ICAM, CD30L, CD40, CD70, CD83, HLA-G, MICA, M1CB, HVEM, lymphotoxin beta receptor, 3/TR6, ILT3, ILT4, an agonist or antibody that binds Toll ligand receptor and a ligand that specifically binds with B7-H3.
  • a co-stimulatory ligand also encompasses, inter alia, an antibody that specifically binds with a co-stimulatory molecule present on a T cell, such as but not limited to, CD27, CD28, 4-IBB, OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LTGHT, NKG2C, B7-H3, a ligand that specifically binds with CD83.
  • an antibody that specifically binds with a co-stimulatory molecule present on a T cell such as but not limited to, CD27, CD28, 4-IBB, OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LTGHT, NKG2C, B7-H3, a ligand that specifically binds with CD83.
  • a “co-stimulatory molecule” refers to the cognate binding partner on a Tcell that specifically binds with a co-stimulatory ligand, thereby mediating a co-stimulatory response by the cell, such as, but not limited to proliferation.
  • Co-stimulatory molecules include, but are not limited to an MHC class I molecule, BTLA and Toll ligand receptor.
  • a “co-stimulatory signal” as used herein refers to a signal, which in combination with primary signal, such as TCR/CD3 ligation, leads to T cell proliferation and/or upregulation or downregulation of key molecules.
  • extracellular ligand-binding domain is defined as an oligo- or polypeptide that is capable of binding a ligand.
  • the domain will be capable of interacting with a cell surface molecule.
  • the extracellular ligand-binding domain may be chosen to recognize a ligand that acts as a cell surface marker on target cells associated with a particular disease state.
  • cell surface markers that may act as ligands include those associated with viral, bacterial and parasitic infections, autoimmune disease and cancer cells.
  • subject or “patient” as used herein includes all members of the animal kingdom including non-human primates and humans.
  • the inventors propose to explore three different strategies to prevent allogeneic CAR T cells depletion via HvG ( FIG. 9 ).
  • the first one consists of expressing PD-L1 at the surface of CAR T cell.
  • the presence of such antigen is likely to inhibit host T cells via PD1/PD-L1 inhibition pathway and thus decrease their cytolytic activity toward CAR T cell ( FIG. 10A ).
  • host T cells are expected to attack and deplete allogeneic CAR T cells ( FIG. 10B ).
  • the second strategy consists of engineering CAR T cells to make them excrete CTLA4 Ig, a chimeric construction made out of CTLA4 protein fused the constant region of IgG.
  • CTLA4 Ig Release of CTLA4 Ig in the extracellular medium is likely to bind to CD86/CD80 exposed at the surface of antigen presenting cells (APC) and prevent them to activate host T cells via CD28/CD80 or CD28/CD86 interactions.
  • the HvG reaction involving host APC and host T cells interaction/activation, is displayed in FIG. 11A and the prevention of CAR T cell rejection via excretion of CTLA4 Ig is displayed in FIG. 11B .
  • the third strategy consisting of combining the two aforementioned strategies, could also been used to prevent HvG reaction and allow CAR T cells to proliferate in the setting of an allogeneic cell adoptive transfer.
  • the inventors describe a method to prevent NK-cell mediated rejection of therapeutic allogeneic T cells by engineering the allogenic T cells through the inactivation of the B2M gene using specific TALEN, combined to either: i) the expression of a chimeric single chain molecule composed of UL18 and ⁇ 2-m (B2M-UL18) or ii) the secretion of NKG2D ligands.
  • the particularity resides in applying to primary T cells a mechanism occurring normally in tumor cells or virally infected cells.
  • the mechanism of action is potentially different: in tumor cells, shedding NKG2D ligands leads to their decreased presence at the surface whereas in engineered cells, secreted the NKG2D ligand(s) would serve as a decoy for several other NKG2D ligands potentially still present at the T cell surface.
  • T cells were purified from Buffy coat samples provided by EFS (Etableau Francais du Sang, Paris, France) using Ficoll gradient density medium. The PBMC layer was recovered and T cells were purified using a commercially available T-cell enrichment kit. Purified T cells were activated in X-VivoTM-15 medium (Lonza) supplemented with 20 ng/mL Human IL-2, 5% Human, and Dynabeads Human T activator CD3/CD28 at a bead:cell ratio 1:1 (Life Technologies).
  • Transfections were done at Day 4 or Day 11 after T-cell purification and activation. 5 millions of cells were transfected with 15 ⁇ g of mRNA encoding the different scCAR constructs.
  • scCAR mRNAs were produced using T7 mRNA polymerase transfections done using Cytopulse technology, by applying two 0.1 mS pulses at 3000V/cm followed by four 0.2 mS pulses at 325V/cm in 0.4 cm gap cuvettes in a final volume of 200 ⁇ l of “Cytoporation buffer T” (BTX Harvard Apparatus). Cells were immediately diluted in X-VivoTM-15 media and incubated at 37° C. with 5% CO 2 . IL-2 was added 2 h after electroporation at 20 ng/mL.
  • T-cells were incubated in 96-well plates (100,000 cells/well), together with 10,000 target cells (expressing CD123) and 10,000 control (CD123neg) cells in the same well.
  • Target and control cells were labelled with fluorescent intracellular dyes (CFSE or Cell Trace Violet) before co-culturing them with CD123 CAR+ T-cells.
  • the co-cultures were incubated for 4 hours at 37° C. with 5% CO 2 . After this incubation period, cells were labelled with a fixable viability dye and analyzed by flow cytometry. Viability of each cellular population (target cells or CD123 control cells) was determined and the % of specific cell lysis was calculated. Cytotoxicity assays were carried out 48 h after mRNA transfection.
  • scCAR detection at the surface of T-cells was done using a recombinant protein consisting on the fusion of the extracellular domain of the human CD123 protein, together with a murine IgG1 Fc fragment. Binding of this protein to the scCAR molecule was detected with a fluorochrome-conjugated secondary antibody targeting the mouse Fc portion of the protein, and analyzed by flow cytometry.
  • Example 1 Transgenic Expression of PD-L1 at the Surface of Primary T Cells and CAR T Cells
  • This example describes expression of PD-L1 at the surface of T cells or CAR T cells along with the impact of such expression on their cytolytic activity toward tumor cells.
  • primary T cells were first purified from buffy-coat samples, activated transduced by a lentiviral particle containing an anti-CD19 CAR tool (pCLS23856, SEQ ID NO 77) and transfected according to the procedure described in Galetto R et al. (2014) Molecular Therapy—Methods & Clinical Development 1, Article number: 14021 doi:10.1038/mtm.2014.2. Briefly regarding transduction, 2 days post activation by Dynabeads human T activator CD3/CD28, T cells were incubated with lentiviral particles containing anti-CD19 CAR tool at 5 MOI.
  • CAR T cells or T cells were transfected with 20 ⁇ g of mRNA encoding PD-L1 (pCLS27069, SEQ ID NO 18).
  • Transfection was performed using Agilpulse technology, by applying two 0.1 mS pulses at 3,000 V/cm followed by four 0.2 mS pulses at 325 V/cm in 0.4 cm gap cuvettes and a final volume of 200 ⁇ l of Cytoporation buffer T (BTX Harvard Apparatus, Holliston, Mass.). Cells were then immediately diluted in X-Vivo-15 media supplemented by 20 ng/ml IL-2 (final concentration) and 5% human serum AB.
  • Transfected T cells were eventually diluted at 1 ⁇ 10 6 /ml and kept in culture at 37° C. in the presence of 5% CO 2 and 20 ng/ml IL-2 (final concentration) and 5% human AB serum for further characterization.
  • CAR T cells were recovered to characterize the expression of PD-L1 at their cell surface and to determine the impact of such expression on their specific cytolytic activity toward relevant tumor cells targeted by their anti CD19 tool CAR.
  • a LV vector containing the PD-L1 cDNA was produced.
  • Primary T cells were first purified from buffy-coat samples, activated, transduced either with a lentiviral particle containing PD-L1 (pCLS27062 of SEQ ID NO.18) at a MOI of 5. Three days post transduction, transduced T cells were recovered to characterize the expression of PD-L1 at their cell surface.
  • Abatacept and belatacept are fusion proteins composed of the Fc region of the immunoglobulin IgG1 fused to the extracellular domain of CTLA-4.
  • This example describes the expression and excretion of CTLA4a Ig and CTLA4b Ig (Abatacept, or Belatacept pCLS27068 SEQ ID NO 3 and pCLS27066, SEQ ID NO 4 respectively) and by LV containing the CTLA4Ig (pCLS27064 of SEQ ID NO.16) at a MOI of 5 by primary T cells in the culture media.
  • Abatacept is described in Moreland L et al; (2006) Nature Reviews Drug Discovery 5, 185-186.
  • Belatacept is described by Larsen C P et al. (2005) “ Rational development of LEA 29 Y ( belatacept ), a high - affinity variant of CTLA 4- Ig with potent immunosuppressive properties ”. Am J Transplant. 5(3):443-53.
  • CTLA4 Ig by primary T cells
  • primary T cells were first purified from buffy-coat samples, activated transduced by a lentiviral particle containing an anti-CD19 CAR tool (pCLS23856, SEQ ID NO 77) and transfected according to the procedure described as in example 1.
  • pCLS23856, SEQ ID NO 77 an anti-CD19 CAR tool
  • 5 days after their activation 5 million of CAR T cells or T cells were transfected with 20 ⁇ g of mRNA encoding CTLA4a or b Ig (Abatacept, or Belatacept pCLS27068 SEQ ID NO:16 and pCLS27066, SEQ ID NO:17 respectively) and cultured according to the protocol described in example 1.
  • CAR T cells were recovered to characterize their ability to excrete CTLA4 Ig in the culture media via ELISA and to determine the impact of such expression/excretion on their specific cytolytic activity toward relevant and non-relevant tumor cells targeted (Daudi and K562 respectively).
  • the results showed that PD-L1 is expressed in T cell transduced with LV vector encoding PD-L1 alone (>70% of cells express PD-L1, FIG. 17 ) or in T cells co transduced with LV vectors encoding PD-L1 and CTLA4Ig (59%) whereas no expression could be detected in untransduced T cells or CTLA4Ig-transduced T cells.
  • PBMCs are labeled with CFSE and mixed with unlabeled, mitomycin-treated or irradiated engineered T cells (donor 2) meaning that they cannot proliferate.
  • flow cytometry analysis is performed with the following gating strategy: FSC/SSC ⁇ viable cells ⁇ CD3+ (T cells from donor 1 PBMCs) ⁇ CFSE. Decrease of CFSE staining is indicative of cell division and thus of allogeneic response of donor 1's T cells due to the presence of HLA mismatched donor 2's T cells.
  • CD3+ T cells do not proliferate when not co-cultured (a) or in the presence au autologous T cells (c).
  • PBMCs from donor 1 As expected CFSE positive population is decreasing as PHA concentration increases.
  • CD3+ T cells do proliferate (disappearance of CFSE positive population) in the presence of allogeneic T cells (c).
  • allogeneic T cells are engineered to express PD-L1 (d), CTLA4Ig (e) or both (f), it is observed that responder T cells keep a bright CFSE staining, leading to the conclusion that the expression PD-L1 and/or CTLA4Ig by engineered T cells inhibit the responder proliferation.
  • results obtained in FIG. 18 show that engineered T cells expressing PD-L1, CTLA4Ig or both are less prone to stimulate allogeneic T cells response in an in vitro mixed lymphocytes reaction (MLR) assay. Moreover, the results show a cumulative effect when both PD-L1, CTLA4Ig are expressed.
  • MLR mixed lymphocytes reaction
  • Example 5 Cytotoxicity Assay Testing Anti-CD123 CAR T Cells Expressing PD-L1 and/or CTLA4Ig for their Capacity to Kill MOLM13 Target Cells
  • This experiment is aimed to test T cells expressing PD-L1 and/or CTLA4Ig for their capacity to kill specific target cells through the expression of a CAR molecule.
  • FIG. 19 and FIG. 20 show that engineered T cells expressing PD-L1, CTLA4Ig or both, and further engineered to express a CD123 CAR molecule, sustain their capacity to kill specific target. Furthermore, these data suggest that expression of PD-L1, CTLA4Ig or both, increase their intrinsic cytolytic activity.
  • the aim of these experiments is to verify that modified T cells are still able to eradicate cognate tumor cells in vivo.
  • an in vivo experiment has been conducted to investigate whether the expression of PD-L1, CTLA4Ig or both impact the CAR T cells anti-tumor activity.
  • the protocol outline is shown in FIG. 21 .
  • Activated T cells were obtained for the following groups of treatment:
  • T cells were amplified in G-Rex for in vivo experiments. After 19 days cells were recovered and counted.
  • FIG. 22 shows that engineered T cells expressing PD-L1, CTLA4Ig or both, and further engineered to express a CD123 CAR molecule sustain similar proliferative capacity as compared to CAR CD123 engineered T cells.
  • T cells thus obtained were injected in NOG mice for in vivo experiment.
  • Immunodeficient NOG mice were intravenously (iv) injected with (CD123 expressing_MOLM13-Luciferase cells as an AML xenograft mouse model. Mice were then iv injected (either 2 or 7 days after injection of the tumor cell line) with different doses of CD123 CAR+ T-cells to be tested, or with T-cells that were not transduced with the CD123 CAR lentiviral vector. Bioluminescent signals were determined at the day of T-cell injection (D0), at D7 and D14 after T-cell injection in order to follow tumoral progression on the different animals.
  • Bioluminescence analysis results from FIG. 23A and FIG. 23B indicate that all groups of mice injected with engineered CAR T cells eradicate efficiently the tumor as compared to control group, and a clear anti-tumor activity of engineered CAR T cells in vivo.
  • HCMV UL18 encodes a type I transmembrane glycoprotein that shares a high level of AA sequence identity with MHC Class I molecules that associates with beta2-m and binds endogenous peptides. Since our goal is to express this molecule in T cells where B2M gene has been invalidated, our strategy is to produce a chimeric molecule where beta2-m and UL18 is fused as a single chain polypeptide. SEQ ID NO 39 shows the amino-acid sequence of the chimeric protein. Lentiviral particles containing the chimeric B2M-UL18 are transduced into T cells. Expression of transgene is monitored by FACS analysis using a beta2-m antibody. The results from this experiment aim to show that a B2M-UL18 chimeric protein is efficiently expressed in T cells.
  • NKG2D natural ligands are transmembrane or GPI-anchored proteins. In order to achieve secretion of these molecules by T cells, the extra-cellular domains of NKG2D ligands have been fused in their N-terminus to a secretory peptide form. Amino-acid sequences of secreted chimeric NKG2D ligands are listed below (SEQ ID NO:40 to SEQ ID NO:47). Lentiviral particles containing the chimeric NKG2D ligands are transduced into T cells. Expression of transgene in culture supernatant is monitored by Western Blot analysis using specific antibodies. The results from this experiment aim to show that chimeric NKG2D ligand proteins are efficiently expressed in T cells.
  • PBMCs from healthy donor A is co-cultured with irradiated or mitomycin-treated engineered beta2-m deficient T cells from donor B.
  • PBMCs from healthy donor A is co-cultured with irradiated or mitomycin-treated engineered beta2-m positive T cells from donor B.
  • cells proliferation from donor A is measured by XTT colorimetric assay or by CFSE dilution (FACS analysis). Although cell proliferation is observed in control, no or limited cell proliferation is observed when engineered T cells do not express beta2-m. The results from this experiment aim to show that alloreactive T cells are not able to recognize and proliferate against beta2-m deficient T cells.
  • Example 11 Efficient Inhibition of NK Mediated Engineered T Cells Lysis
  • NK cells are purified from healthy donor A PBMCs.
  • engineered T cells from healthy donor B are produced and listed below. a) engineered T cells (negative control), b) beta2-m deficient engineered T cells (positive control), c) beta2-m deficient engineered T cells expressing B2M-UL18 (SEQ ID NO 39), d-k) beta2-m deficient engineered T cells expressing respectively SP-MICAed (SEQ ID No.
  • NK mediated cell lysis is observed in the positive control (beta2-m deficient engineered T cells) or secreted NKG2D ligands (SP-MICAed (SEQ ID NO 40), SP-MICBed (SEQ ID NO 41), SP-ULBP1ed (SEQ ID NO 42), SP-ULBP2ed (SEQ ID No.
  • MMLV Moloney Murine Leukemia Virus
  • Lentiviral particles bearing secreted 9-mer FP polypeptides (1 from HIV-1 virus and 2 from artificial sequence with respective SEQ ID NO 48 and 49-50) are transduced into T cells. Expression of secreted FP peptides is monitored in cell culture supernatant by western blot. The results from this experiment aim to show that secreted FP peptides are efficiently expressed in T cells.
  • Example 14 Efficient Inhibition of T Cells Proliferation Towards Engineered T Cells Expressing ISU
  • PBMCs from healthy donor A is co-cultured with irradiated or mitomycin-treated engineered T cells from donor B, expressing ISU.
  • PBMCs from healthy donor A is co-cultured with irradiated or mitomycin-treated engineered T cells from donor B that do not express ISU.
  • cells proliferation from donor A is measured by XTT colorimetric assay or by CFSE dilution (FACS analysis). Although cell proliferation is observed in control, no or limited cell proliferation is observed when engineered T cells express membrane bound or secreted ISU. The results from this experiment aim to show that alloreactive T cells proliferation is inhibited when engineered T cells express ISU.
  • Example 15 Efficient Inhibition of T Cells Proliferation Towards Engineered T Cells Expressing FP
  • PBMCs from healthy donor A is co-cultured with irradiated or mitomycin-treated engineered T cells from donor B, expressing FP.
  • PBMCs from healthy donor A is co-cultured with irradiated or mitomycin-treated engineered T cells from donor B that do not express FP.
  • cells proliferation from donor A is measured by XTT colorimetric assay or by CFSE dilution (FACS analysis). Although cell proliferation is observed in control, no or limited cell proliferation is observed when engineered T cells express secreted FP. The results from this experiment aim to show that alloreactive T cells proliferation is inhibited when engineered T cells express FP.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
US15/556,558 2015-03-11 2016-03-11 Methods for engineering allogeneic T cell to increase their persistence and/or engraftment into patients Active 2038-05-12 US11186824B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201570138 2015-03-11
DKPA201570138 2015-03-11
PCT/EP2016/055332 WO2016142532A1 (en) 2015-03-11 2016-03-11 Methods for engineering allogeneic t cell to increase their persistence and/or engraftment into patients

Publications (2)

Publication Number Publication Date
US20180291343A1 US20180291343A1 (en) 2018-10-11
US11186824B2 true US11186824B2 (en) 2021-11-30

Family

ID=52682595

Family Applications (1)

Application Number Title Priority Date Filing Date
US15/556,558 Active 2038-05-12 US11186824B2 (en) 2015-03-11 2016-03-11 Methods for engineering allogeneic T cell to increase their persistence and/or engraftment into patients

Country Status (12)

Country Link
US (1) US11186824B2 (enrdf_load_stackoverflow)
EP (1) EP3268388A1 (enrdf_load_stackoverflow)
JP (1) JP2018509148A (enrdf_load_stackoverflow)
KR (1) KR20170137079A (enrdf_load_stackoverflow)
CN (1) CN107683333A (enrdf_load_stackoverflow)
AU (1) AU2016231061B2 (enrdf_load_stackoverflow)
BR (1) BR112017018224A2 (enrdf_load_stackoverflow)
CA (1) CA2978840A1 (enrdf_load_stackoverflow)
IL (1) IL253879A0 (enrdf_load_stackoverflow)
MX (1) MX2017011418A (enrdf_load_stackoverflow)
RU (1) RU2017134441A (enrdf_load_stackoverflow)
WO (1) WO2016142532A1 (enrdf_load_stackoverflow)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190010514A1 (en) * 2014-03-11 2019-01-10 Cellectis Method for generating t-cells compatible for allogenic transplantation

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108135935A (zh) 2015-07-21 2018-06-08 儿童医疗中心有限公司 表达pd-l1的造血干细胞及其用途
EA201891338A1 (ru) 2015-12-04 2018-12-28 Новартис Аг Композиции и способы для иммуноонкологии
IL265438B2 (en) * 2016-09-23 2023-10-01 Univ Southern California Chimeric antigen receptors and compositions and methods of use thereof
WO2018115189A1 (en) 2016-12-21 2018-06-28 Cellectis Stably enginereed proteasome inhibitor resistant immune cells for immunotherapy
KR20240095477A (ko) * 2017-01-13 2024-06-25 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 면역조작된 만능 세포
EA201992232A1 (ru) 2017-03-22 2020-05-14 Новартис Аг Композиции и способы для иммуноонкологии
CA3057265A1 (en) * 2017-04-19 2018-10-25 Allogene Therapeutics, Inc. Improved t cell compositions and methods
CN107177632B (zh) * 2017-05-27 2020-02-07 上海优卡迪生物医药科技有限公司 一种基于octs技术的髓系白血病car-t治疗载体及其构建方法和应用
CN110831970B (zh) 2017-06-02 2024-12-17 辉瑞公司 靶向flt3的嵌合抗原受体
US11879137B2 (en) 2017-09-22 2024-01-23 The Children's Medical Center Corporation Treatment of type 1 diabetes and autoimmune diseases or disorders
EP3684919A1 (en) * 2017-10-19 2020-07-29 Cellectis Targeted gene integration of nk inhibitors genes for improved immune cells therapy
CN109836497A (zh) * 2017-11-25 2019-06-04 深圳宾德生物技术有限公司 一种靶向egfr的单链抗体、嵌合抗原受体t细胞及其制备方法和应用
EP3694546A1 (en) 2018-01-30 2020-08-19 Cellectis Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen
WO2019154313A1 (zh) * 2018-02-11 2019-08-15 江苏恒瑞医药股份有限公司 一种分离的嵌合抗原受体以及包含其的修饰t细胞及用途
AU2019260705B2 (en) * 2018-04-26 2024-10-10 Baylor College Of Medicine Auto/allo-immune defense receptors for the selective targeting of activated pathogenic T cells and NK cells
GB201813178D0 (en) * 2018-08-13 2018-09-26 Autolus Ltd Cell
CN109055380B (zh) * 2018-09-19 2021-08-27 深圳市菲鹏生物治疗股份有限公司 一种通用型car-t细胞的制备方法
CN112739817B (zh) * 2018-09-21 2025-01-24 克莱格医学有限公司 表达有嵌合受体的t细胞
CN109293773B (zh) * 2018-09-25 2020-09-04 上海邦耀生物科技有限公司 靶向cd38蛋白的抗体、嵌合抗原受体和药物
SG11202103832SA (en) * 2018-11-07 2021-05-28 Crispr Therapeutics Ag Anti-cd33 immune cell cancer therapy
BR112021015676A2 (pt) 2019-02-15 2021-10-05 University Of Southern California Composições de anticorpo lym-1 e lym-2 e construções car aprimoradas
US20220220561A1 (en) * 2019-03-18 2022-07-14 Advanced ReGen Medical Technologies, LLC Methods and clinical protocols and kits pertaining to making and using therapeutic compositions for cellular treatment
US12006511B2 (en) 2019-04-15 2024-06-11 The Medical College Of Wisconsin, Inc. Recombinant PD-L1 peptides and methods of use
BR112021022458A2 (pt) 2019-05-10 2021-12-28 Univ California Células pluripotentes modificadas ou uma célula derivada das mesmas, método de transplantar uma célula, método de tratamento de uma doença em um paciente em necessidade de células transplantadas, método para gerar uma célula pluripotente modificada, método para gerar uma célula hipoimunogênica pluripotente, e método de transplante de uma célula pluripotente hipoimunogênica (hip) ou célula derivada da mesma
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
CN120485288A (zh) * 2019-06-26 2025-08-15 武田药品工业株式会社 转染方法
US20220288118A1 (en) * 2019-07-31 2022-09-15 Forty Seven, Inc. Depletion regimes for engineered t-cell or nk-cell therapy
KR20220124173A (ko) 2019-12-11 2022-09-13 에이투 바이오쎄라퓨틱스, 인크. Lilrb1-기반 키메라 항원 수용체
KR102246067B1 (ko) * 2020-05-13 2021-04-29 (주)세렌라이프 효능이 증진된 줄기세포를 포함하는 세포 생착능 증진용 조성물
JPWO2021241658A1 (enrdf_load_stackoverflow) * 2020-05-26 2021-12-02
KR20230052291A (ko) 2020-08-20 2023-04-19 에이투 바이오쎄라퓨틱스, 인크. Ceacam 양성 암을 치료하기 위한 조성물 및 방법
CA3188862A1 (en) 2020-08-20 2022-02-24 Carl Alexander Kamb Compositions and methods for treating mesothelin positive cancers
ES2984902T3 (es) 2020-08-20 2024-10-31 A2 Biotherapeutics Inc Composiciones y métodos para tratar cánceres positivos para EGFR
US20240000938A1 (en) * 2020-11-24 2024-01-04 A2 Biotherapeutics, Inc. Adoptive cell therapy for treatment of cancer associated with loss of heterozygosity
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
JP2024510184A (ja) * 2021-03-10 2024-03-06 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド 治療用ｔ細胞毒性を減少させるための組成物および方法
WO2024003349A1 (en) 2022-07-01 2024-01-04 Novo Nordisk A/S Enhancing neuronal differentiation of ventral midbrain neural progenitor cells
WO2025003393A1 (en) 2023-06-30 2025-01-02 Novo Nordisk A/S Enhancing neuronal differentiation of neural progenitor cells

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017911A1 (en) 1993-12-30 1995-07-06 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US20050214313A1 (en) * 2000-05-26 2005-09-29 Peach Robert J Soluble CTLA4 mutant molecules and uses thereof
WO2005097160A2 (en) 2004-04-05 2005-10-20 The Regents Of The University Of California Modulation of nkg2d
US20060222633A1 (en) 2000-05-11 2006-10-05 Yale University Prevention, decrease, and/or treatment of immunoreactivity by depleting and/or inactivating antigen presenting cells in the host
WO2011064779A2 (en) 2009-11-29 2011-06-03 Yeda Research And Development Co. Ltd. PEPTIDES DERIVED FROM HIV-1 gp41 TRANSMEMBRANE DOMAIN AND METHODS OF USE THEREOF
WO2011109789A2 (en) 2010-03-05 2011-09-09 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
US20130315884A1 (en) * 2012-05-25 2013-11-28 Roman Galetto Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
WO2014184744A1 (en) 2013-05-13 2014-11-20 Cellectis Methods for engineering highly active t cell for immunotherapy
WO2014184741A1 (en) 2013-05-13 2014-11-20 Cellectis Methods for engineering allogeneic and highly active t cell for immunotheraphy
WO2014191128A1 (en) 2013-05-29 2014-12-04 Cellectis Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US6010613A (en) 1995-12-08 2000-01-04 Cyto Pulse Sciences, Inc. Method of treating materials with pulsed electrical fields
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
CA2406864A1 (en) 2000-02-24 2001-08-30 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US9982251B2 (en) 2003-03-14 2018-05-29 Cellectis S.A. Large volume ex vivo electroporation method
US9315788B2 (en) 2011-04-05 2016-04-19 Cellectis, S.A. Method for the generation of compact TALE-nucleases and uses thereof
MX368507B (es) 2012-05-15 2019-10-07 Bristol Myers Squibb Co Uso de un anticuerpo anti-pd-1 en combinación con un anticuerpo anti-ctla-4 en la manufactura de un medicamento para el tratamiento de cáncer.
PT2893004T (pt) 2012-09-04 2019-01-21 Cellectis Recetor de antígeno quimérico de cadeia múltipla e utilizações do mesmo
US9902973B2 (en) 2013-04-11 2018-02-27 Caribou Biosciences, Inc. Methods of modifying a target nucleic acid with an argonaute
TR201819571T4 (tr) 2014-02-14 2019-01-21 Cellectis Hem immün hücrelerde hem de patolojik hücrelerde bulunan antijenleri hedef almak amacıyla değiştirilmiş immünoterapiye yönelik hücreler.
DK3119807T3 (da) 2014-03-19 2019-07-15 Cellectis Cd123-specifikke kimære antigenreceptorer til cancerimmunterapi

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017911A1 (en) 1993-12-30 1995-07-06 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US20060222633A1 (en) 2000-05-11 2006-10-05 Yale University Prevention, decrease, and/or treatment of immunoreactivity by depleting and/or inactivating antigen presenting cells in the host
US20050214313A1 (en) * 2000-05-26 2005-09-29 Peach Robert J Soluble CTLA4 mutant molecules and uses thereof
WO2005097160A2 (en) 2004-04-05 2005-10-20 The Regents Of The University Of California Modulation of nkg2d
WO2011064779A2 (en) 2009-11-29 2011-06-03 Yeda Research And Development Co. Ltd. PEPTIDES DERIVED FROM HIV-1 gp41 TRANSMEMBRANE DOMAIN AND METHODS OF USE THEREOF
WO2011109789A2 (en) 2010-03-05 2011-09-09 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
US20130315884A1 (en) * 2012-05-25 2013-11-28 Roman Galetto Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
WO2014184744A1 (en) 2013-05-13 2014-11-20 Cellectis Methods for engineering highly active t cell for immunotherapy
WO2014184741A1 (en) 2013-05-13 2014-11-20 Cellectis Methods for engineering allogeneic and highly active t cell for immunotheraphy
WO2014191128A1 (en) 2013-05-29 2014-12-04 Cellectis Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system

Non-Patent Citations (21)

* Cited by examiner, † Cited by third party
Title
Blast Alignment, 2020. *
Blazar, J. Immunol., 2003, 171: 1272-1277. *
Cooper et al: "Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma", Oncoimmunology, vol. 2, No. 5, May 1, 2013, p. e24320.
Curran et al: "PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors", Proceedings of the National Academy of Sciences, vol. 107, No. 9, Mar. 2, 2010, pp. 4275-4280.
Dotti et al., Blood, 2009, 114: 1457-1458. *
European Patent Office, International Search Report for International Appln. PCT/EP2016/055332, dated May 31, 2016.
Favier et al., PLoS One, 2011,6: 1-8. *
John et al: "Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells", Clinical Cancer Research, The American Association for Cancer Research, US, vol. 19, No. 20, Oct. 15, 2013, pp. 5636-5646.
Mincheva-Nilsson et al., J. Immunol., 2006, 176: 3585-3592. *
Moon et al., Multifactorial T cell Hypofunction that is Reversible Can Limit the Efficacy of Chimeric Antibody Receptor-transduced Human T cells in Solid Tumors, Clin Cancer Res. Aug. 15, 2014; 20(16): 4262-4273.
Pardoll, Nat. Rev. Cancer, 2012, 12: 252-264. *
Reyburn et al., Nature, 1997, 386: 514-517. *
Riolobos et al., Mol. Ther., 2013, 21: 1232-1241. *
Rong et al., "An Effective Approach to Prevent Immune Rejection of Human ESC-Derived Allografts" Cell Stem Cell 14, 121-130, Jan. 2, 2014.
Rong et al., Cell Stem Cell, Jan. 2, 2014, 14: 121-130. *
Sequence alignment_16, 2020. *
Sequence alignment_17, 2020. *
Sequence alignment_18, 2020. *
Thell et al., "Immunosuppressive peptides and their therapeutic applications", Drug Discov. Today., May 2014; 19(5): 645-653.
Torikai et al: "A foundation foruniversal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR", Blood, vol. 119, No. 24, Jun. 14, 2012, pp. 5697-5705.
Wilkinson et al: "Modulation of natural killer cells by human cytomegalovirus", Journal of Clinical Virology, Elsevier, Amsterdam, NL, vol. 41, No. 3, Feb. 15, 2008, pp. 206-212.

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190010514A1 (en) * 2014-03-11 2019-01-10 Cellectis Method for generating t-cells compatible for allogenic transplantation
US11820996B2 (en) * 2014-03-11 2023-11-21 Cellectis Method for generating T-cells compatible for allogenic transplantation
US12252699B2 (en) 2014-03-11 2025-03-18 Cellectis Method for generating t-cells compatible for allogenic transplantation

Also Published As

Publication number Publication date
CA2978840A1 (en) 2016-09-15
WO2016142532A1 (en) 2016-09-15
BR112017018224A2 (pt) 2018-04-17
JP2018509148A (ja) 2018-04-05
US20180291343A1 (en) 2018-10-11
MX2017011418A (es) 2017-12-14
IL253879A0 (en) 2017-10-31
AU2016231061B2 (en) 2020-11-26
KR20170137079A (ko) 2017-12-12
RU2017134441A (ru) 2019-04-03
RU2017134441A3 (enrdf_load_stackoverflow) 2019-09-26
CN107683333A (zh) 2018-02-09
AU2016231061A1 (en) 2017-08-31
EP3268388A1 (en) 2018-01-17

Similar Documents

Publication Publication Date Title
US11186824B2 (en) Methods for engineering allogeneic T cell to increase their persistence and/or engraftment into patients
US11891614B2 (en) Methods for engineering allogeneic and immunosuppressive resistant T cell for immunotherapy
US11304975B2 (en) Methods for engineering allogeneic and highly active t cell for immunotherapy
US20230050345A1 (en) Methods for engineering allogeneic and highly active t cell for immunotheraphy
HK40067501A (en) Methods for engineering allogeneic and highly active t cell for immunotheraphy
HK40071469A (en) Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
HK40001542A (en) Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

AS Assignment

Owner name: CELLECTIS, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DUCHATEAU, PHILIPPE;CABANIOLS, JEAN-PIERRE;VALTON, JULIEN;AND OTHERS;SIGNING DATES FROM 20171115 TO 20171120;REEL/FRAME:044250/0026

STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 4